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Abstract 
Von Willebrand disease (VWD) is the most common inherited bleeding disorder. It is caused 
by a deficiency of the von Willebrand factor (VWF), a protein involved in the haemostasis 
process. VWD is a very heterogeneous disease with many recognised typologies; type 1 VWD 
is the most common variant, covering almost 65% of the total cases. Type 1 VWD comprises 
several subtypes, making the disease diagnosis a complex task, which has to be carried out in 
specialized centres by expert medical practitioners. In many cases, DNA sequencing is required 
to obtain a certain diagnosis. However, about 35% of subjects affected by type 1 VWD do not 
carry any gene mutation, making even this test ineffective. 
A pharmacokinetic model has been exploited to characterize each type 1 VWD subject and 
estimate useful pharmacokinetic indexes. These indexes and experimental measurements have 
been used to train support vector machine classifiers, proposing a model-based algorithm to 
support the diagnosis of type 1 disease variant. The results show that the implemented algorithm 
correctly classifies the subjects in about 90% of cases, thus representing a promising tool for 
reducing medical effort and improving patient lives. 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Riassunto 
La malattia di von Willebrand (VWD) è una delle più comuni malattie ereditarie che interessa 
il processo di coagulazione del sangue. La malattia è causata da un’insufficienza del fattore di 
von Willebrand (VWF), una proteina multimerica che permette l’adesione delle piastrine al 
vaso sanguineo danneggiato fermando il sanguinamento. La malattia è molto eterogenea ed in 
particolare lo è la variante più comune chiamata “tipo 1”, caratterizzata da un’insufficienza 
quantitativa del VWF e rappresentativa del 65% circa dei casi di VWD.  
La diagnosi è resa difficile dalla presenza di molti fattori, fisiologici ed ambientali, che 
influenzano il livello di VWF nel sangue. Inoltre, i sintomi, che tipicamente includono fenomeni 
emorragici, non sono specifici della malattia. Ciò comporta un lungo procedimento che 
comprende diversi test clinici per ottenere una diagnosi, che spesso richiede il sequenziamento 
del DNA per essere confermata.  
Recenti studi hanno portato allo sviluppo di diversi modelli farmacocinetici per descrivere i 
fenomeni che interessano il VWF dopo il suo rilascio nel plasma. Tali modelli sono utilizzati 
sia per avere una migliore comprensione della malattia, sia per sviluppare dei metodi che 
possano essere di supporto al lavoro del personale medico specializzato durante la diagnosi. 
In questo lavoro di ricerca, la categoria “tipo 1 VWD” è stata analizzata e caratterizzata 
attraverso l’utilizzo di un modello farmacocinetico in grado di descrivere i tre principali 
fenomeni che interessano il VWF: il rilascio, la proteolisi e l’eliminazione. I dati sperimentali 
sono stati forniti grazie alla collaborazione con l’azienda ospedaliera di Padova. 
Successivamente, è stato possibile proporre un algoritmo che, utilizzando sia dati sperimentali 
sia informazioni ottenute dal modello farmacocinetico, attraverso tecniche di analisi dati e di 
apprendimento supervisionato per la classificazione, sia in grado di riconoscere se un soggetto 
sia affetto da VWD di tipo 1 o sia sano e, in caso sia malato, se la malattia sia riconducibile alla 
presenza di una mutazione nel gene che codifica il VWF oppure no. 
I risultati mostrano una buona capacità del modello farmacocinetico di descrivere i soggetti 
malati di VWD di tipo 1, evidenziando le principali differenze tra le varie tipologie di soggetti 
malati caratterizzate da diverse tipologie di mutazioni.  
L’algoritmo proposto, in fase di validazione, è in grado di classificare correttamente se un 
soggetto è malato, oppure sano, in oltre il 90% dei casi analizzati. Se il soggetto è malato, il 
modello di classificazione per determinare la presenza di una mutazione classifica 
erroneamente solo il 2.5% dei casi. 
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Introduction 
The von Willebrand disease (VWD) is one of the most common inherited bleeding disorder and 
is caused by a deficiency of the von Willebrand factor (VWF). VWF is a multimeric protein, 
which helps the platelet adhesion to the damaged blood vessel during the haemostasis process.  
Qualitative deficiency of VWF characterizes variant type 1, which comprises many subtypes 
depending on presence and type of the VWF gene mutation.  
Because of the difficulties to recognise the disease due also to the high heterogeneity of type 1 
VWD, the disease diagnosis is a complex task, and several clinical tests have to be carried out 
by expert practitioners in specialized centres.    
Several pharmacokinetic (PK) models have been developed to describe the phenomena 
involving the VWF after its release in blood plasma. PK models permit to characterize the 
subjects affected by the disease, thus providing a tool for a better disease comprehension; they 
can represent a starting point for proposing model-based approaches assisting medical doctors 
during the diagnosis of the disease. 
In this Thesis a pharmacokinetic model able to quantify the VWF release, proteolysis and 
elimination phenomena, is used to characterized the subjects affected by type 1 VWD. Through 
experimental measurements and pharmacokinetic indexes derived from the model, an 
algorithmic approach supporting the diagnosis of type 1 VWD subtypes is proposed. The Thesis 
is structured as follows. 
In Chapter 1, a general overview of the VWD is given, focusing on the description of the VWF 
synthesis and on the successive proteolysis mechanisms during the haemostasis process. The 
recognised typologies that characterized the VWD depending of the VWF deficiency are 
described. The medical protocol followed to achieve the diagnosis, together with the associated 
clinical test used in this Thesis, is then explained. 
In Chapter 2, the pharmacokinetic model used to characterize the affected subjects is described. 
Particular attention is given to the parameters estimation activity. The mathematical 
methodologies adopted to formulate the diagnostic algorithm are eventually outlined. 
In Chapter 3, the results obtained from the characterization of type 1 VWD subjects through 
the pharmacokinetic model are reported. In the first section, the results will be discussed 
focusing on the differences and similarity between the type 1 category and the healthy and the 
other VWD categories. The second section aims at describing the type 1 VWD subtypes in 
terms of relevant pharmacokinetic indexes. 
In Chapter 4, the proposed model-based diagnosis algorithm, is explained. Classification results 
are reported and discussed. 
Some final remarks and some advice for future work concludes the Thesis. 
  
 
 
 
 
 
 
 
 
 
 
 
  
 
 
  
Chapter 1 
The von Willebrand disease 
In this chapter a general overview on the disease will be given. The role of von Willebrand 
factor (VWF) during the haemostasis process, the VWD categories and the clinical tests used 
for the diagnosis will be discussed. 
 1.1 Introduction to the von Willebrand disease  
Von Willebrand disease (VWD) is one of the most common inherited bleeding disorder 
observed in humans. It was discovered in the 1926 by the Finnish physician Eric von Willebrand 
who took care of a 5 years old girl who showed severe bleeding disorder. What differentiate 
this bleeding disorder from haemophilia A was that it seemed not associated to muscles and 
joints bleeding. Both the girl’s father and mother showed bleeding history, and several her 
sisters died after uncontrolled bleeding (Berntrop, 2007). A clear distinction from the 
haemophilia A was discovered only in the 1980’s; persons who had VWD have a qualitative 
and/or quantitative von Willebrand factor (VWF) deficiency and normal FVIII gene while, 
person who had haemophilia A have an abnormal FVIII gene.  
Based on the number of symptomatic patients seen at haemostasis centres, the VWD prevalence 
estimated values range between 0.0023 and 0.01 percent of the total population. Based, instead, 
on the symptoms estimations, the VWD prevalence values is between 0.6 and 1.3 percent 
(N.H.L.B.I., 2007). These discrepancies shows how difficult a certain VWD diagnosis can be.   
 1.2 The von Willebrand factor 
The von Willebrand factor is a multimeric glycoprotein assembled from identical subunits each 
consisting of 2050 aminoacid residues and up to 22 carbohydrate side chains (Zaverio, 2007). 
VWF is found in circulating blood plasma, subendothelial cells and platelets and can reach a 
molecular weight as 20 million Dalton and a length up to 2 micrometers. 
Von Willebrand factor plays a dual role during the haemostasis process. It helps the platelets 
adhesion to the injured vessel that otherwise, because of the high blood shear rate, would not 
be possible. Furthermore, circulating plasma VWF binds to FVIII preventing its cleavage. FVIII 
is a glycoprotein fundamental for the haemostasis process. 
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Levels of VWF are affected by several factors that includes age, ethnicity, blood group and 
hormones. VWF increasing during pregnancy, with aging and acute stress or inflammation. The 
VWF production rate probably is not affected by blood group, but VWF survival is reduced in 
persons who have type 0 blood.  
1.2.1 The von Willebrand factor synthesis and secretion 
The VWF gene is located at the tip of the short arm of chromosome 12 and it contains 52 exons. 
VWF is synthetized in two cell types; in the vascular endothelium by the endothelial cells and 
in bone narrow by the megakaryocytes. Endothelial synthesis involves the VWF cDNA 
translation that produce a precursor polypeptide referred to as pre-pro-VWF. The pre-pro-VWF 
and the propeptide together represent the pro-VWF, which is entirely composed of four type of 
repeating domains designated A through D. The order in which the different domains are 
arranged is reported in Figure 1.1. In the endoplasmic reticulum, VWF dimers are produced 
from the pre-pro-VWF monomers through disulphide bonds; the last 151 residues, following 
the C2 domain, are the only structure needed to dimerization. In the Golgi apparatus, concurrent 
with or soon after, the propeptide permits the VWF dimers associations, through the D domains, 
into high order polymers (Figure 1.2). (Zaverio 1999; Sadler, 2005).   
The endothelial synthetized VWF can follow two different secretion pathway. A constitutive 
pathway, where the VWF is released as soon as its synthesis is completed, and a regulated 
pathway, where mature VWF is stored in the Weibel-Palade bodies, a rod-shaped organelles 
unique to endothelial cells. The VWF stored in Weibel-Palade bodies has a higher molecular 
mass than the constitutive VWF and it is released after stimulation by secretagogues.  
The megakaryocytes VWF synthesis, because of the difficulties of platelets culturing, has not 
been studied in detail. Although definitive proof is still lacking, it is currently accepted that 
VWF is biosynthesized in megakaryocytes and endothelial cells in much the same way 
(Casonato, 2016). Furthermore, there are no doubt that all the VWF synthetized by 
megakaryocytes is stored in α-ganules of platelets and is released only after platelets activations 
during the haemostasis process (Zaverio, 1999).  
The VWF stored in α-ganules, similarly to the one stored in Weibel-Palade, is composed of the 
largest multimers, showing an enhanced haemostatically action. 
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Figure 1.1. Gene and VWF structures. The exons that codify each pre-pro VWF domains are highlighted (Sadler, 2000).  
 
 
Figure 1.2 VWF dimerization process in the endoplasmic reticulum and VWF synthesis in the Golgi apparatus (Sadler, 
2005).  
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The VWF circulating in plasma is essentially originated by the endothelial cells and is secreted 
following the constitutive pathway. The proteolytic action of ADAMST13 metalloproteinase 
enzyme at the bond between Tyr842 and Met843 in the A2 VWF domain convert the large 
multimers into smaller ones. The A2 domain is exposed to the ADAMST13 actions when VWF 
multimers are subjected to sufficient blood shear rate (Sadler, 2005). Proteolytic actions is 
necessary to prevent the thrombosis formation. Platelet VWF is more resistant to the 
ADAMSTS13 proteolytic action, in fact the VWF subunits fragments produced by plasma 
VWF degradation are not found in platelets VWF (Sadler, 2005). 
VWF multimers are then cleared with a half-life of 12-20 h by a mechanism that not strongly 
depend on multimers size.  
 1.2.2 The haemostasis process and the role of VWF 
Haemostasis is the sum of the physiological processes that allows bleeding stops at the injury 
site, maintaining normal blood flow in the circulation. Four different steps characterize 
haemostasis:  
 Vascular spasm;  
 Primary haemostasis; 
 Secondary haemostasis; 
 Fibrinolysis. 
The vascular spasm is necessary to reduce the blood flow in the injured site and is caused by 
the endothelins releasing from the endothelium. Endothelins are amino-acid peptides with a 
powerful vasoconstriction action. 
Primary haemostasis involves the platelets adhesion to the damaged vessel wall and the 
subsequent growth of the haemostasis plug due to the platelet-platelet interactions. VWF, which 
is released from the sub-endothelium, plays a central role during the primary haemostasis 
process; VWF A3 domain contains the main binding site for collagen. In a normal shear rate 
blood flow (1000 𝑠−1), only binds between GP Iba glycoprotein present on the platelets surface 
and immobilized VWF A1 domain can initiate the platelets adhesion to the vessel wall (Figure 
1.3). The platelet adhesion in low shear rate flow (500 𝑠−1) is not affected by the absence of 
VWF.  
The VWF and platelets bond affect the platelets structure, which released adenosine 
diphosphate and thrombin; this form of platelets is called activated form (Figure 1.4).  The 
change in form of platelets expose the integrin aIIbβ3, which become the binding site for 
adhesive ligand (mainly fibrinogen and VWF) for the additional attachment of platelets 
(Zaverio, 2007).  
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Secondary haemostasis consists of a cascade process that culminates with the activation of 
fibrin (Figure 1.5). The cascade process can be initiate by two events, which characterized two 
pathway, the intrinsic pathway and the extrinsic pathway.  
The extrinsic pathway is activated only after blood vessel injury after the release of tissue factor 
(TF) and produce thrombin, which cleaves fibrinogen to generate insoluble fibrin. Furthermore, 
thrombin activates factor XI that initiates the intrinsic pathway. Intrinsic pathway can be 
activated by blood contacts with extracellular collagen. Factor VIII participates in intrinsic 
pathway and is present in plasma, bounded to VWF to prevent its degradations. The VWF D’-
D3 domains form the site that binds FVIII. 
 
 
Figure 1.3. Platelets adhesion and aggregation. The binding sites between platelets and VWF are highlighted (Kumar, 2015).  
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Figure 1.3. Primary haemostasis process: VWF vessel adhesion, uncoiling and platelets activations (N.H.B.L.I., 2007). 
 
 
Figure 1.4. Secondary haemostasis process scheme (Adapted from N.H.B.L.I., 2007). 
 
Finally, fibrinolysis aims to dissolve the blood clots during the process of wound healing and 
stops the cloth formation in the healthy blood vessels. 
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 1.3 Classification of von Willebrand disease 
Von Willebrand disease appears in several forms and its classification is intended to be clinical 
relevant to its treatment. The 1994 classification reserved the VWD designation for disorders 
caused by VWF gene mutations, but in 2006 this criterion has been dropped because in practice 
it is verifiable for only a small fraction of patients (N.H.L.B.I., 2007). 
VWD is classified into three major categories: type 1 is characterized by partial VWF 
deficiency, type 2 is characterized by qualitative deficiency and type 3 is characterized by total 
deficiency. 
1.3.1 Type 1 VWD 
Type 1 VWD is the most common form of VWD, accounting for about 75 % of the total VWD 
affected subjects. The level of VWF in plasma is low but it mediates platelets adhesion and 
binds FVIII normally.   
VWF is a multimer and a single mutant subunits might impair the intracellular transport of 
VWF dimers or the multimers secretion, decreasing the VWF levels without affects the 
multimers distribution. Sometimes, reduced secretion is not enough to justify low VWF 
concentration, suggesting that an enhanced clearance might contribute (Sadler, 2005). 
VWD type 1 diagnosis is a difficult task. Some cases shows exceptionally low VWF levels, 
repeated and serious bleeding disorders and have dominant negative mutations that interfere 
with the intracellular transport of dimeric pro-VWF or promote its clearance from the 
circulation. The subjects affected by severe type 1 usually have VWF levels lower than 20 
IU/dL while the VWF normal range is between 50 and 200 IU/dL.  
Levels of VWF just below the normal range (30-50 IU/dL) pose a problem for diagnosis. The 
broad VWF normal range significantly overlaps the VWF levels of mild VWD type 1. 
Moreover, VWF deficiency can cause bleeding, but bleeding has many causes so it identifies a 
risk factor for bleeding but does not mandate a diagnosis of type 1 VWD (Sadler, 2003). 
Furthermore, about the 35 % of the mild type 1 VWD affected subjects have no VWF mutations 
(Lillicrap, 2007).  
For all these reasons, a certain diagnosis is often difficult to obtain, and most diagnosis of type 
1 VWD are false positives. The consequences of VWD misdiagnosis are not necessary benign. 
Patients may be exposed to risky, expensive and useful treatments, while the real cause of 
symptoms are untreated (Sadler, 2003).  
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1.3.2 Type 2 VWD  
Type 2 VWD is characterized by a qualitative VWF deficiency. There are many variants of 
type 2 VWD due to the different reasons that cause the anomaly, the following variants are the 
most known.  
 
Type 2A VWD. This variant shows a qualitative deficiency refers to a decreased VWF-
dependent platelet adhesion because the proportion of large VWF multimers is decreased. 
Levels of VWF:Ag and FVIII may be normal or modestly decreased. Type 2A VWD may be 
caused by mutations that interfere with the assembly or secretion of large multimers or that 
increases the VWF multimers proteolytic degradations. Mutations are located in the VWF A2 
domain.  
 
Type 2B VWD. For this variant an increase platelet-VWF affinity occurs. The circulating 
platelets are coated with mutant VWF, which may prevent the platelets adhesion to the injured 
site. Therefore, large, functional VWF multimers are cleaves by the ADAMST13 actions. 
Mutations are located within or adjacent to the VWF A1 domain and involves a VWF 
conformational change, which enhances the VWF-platelet binding. 
 
Type 2N VWD. This variant shows an impaired FVIII binding. FVIII is so exposed to 
degradation. Mutations are located between domains D’ and D3. Because the low FVIII levels, 
type 2N VWD can be masquerades from haemophilia A and specific assay are required to 
prevent misdiagnosis. The capital n stand for Normandy, where the firsts cases where 
discovered. 
 
Type 2M VWD includes variants with decreased VWF-dependetn platelet adhesion not caused 
by the absence of high molecular weight VWF multimers. TYPE 2m mutations does not affect 
the VWF impairing but reduce the VWF interaction with platelet or with connective tissue 
(collagen). Mutations are located in A1 domain, where they interfere with platelet GBIb. 
 
Type Vicenza VWD is a variant with high discrepancy between the plasma and platelets VWF. 
The plasma VWF level is low but the VWF multimers are ultra-large, meaning that the 
metalloproteinase ADAMS-13 is not able to proteolysis VWF. The low VWF level in plasma 
can be explained by an enhanced clearance while normal level of platelets VWF suggests a 
normal synthesis. For these reasons, depending of interpretations of laboratory tests, sometimes 
types Vicenza are classified under type 1 or under type 2M. Mutations for type Vicenza are 
specific of Arg1205His (N.H.L.B.I., 2007). This VWD subtypes is called Vicenza because of 
the place where the specific mutation was found. 
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1.3.3 Type 3 VWD  
Type 3 VWD is characterized by undetectable VWF protein and activity. FVIII level are usually 
very low (< 9 IU/dL). Mutations are distributed throughout the VWF gene and most are unique 
to the family in which they were first identify. Nonsense and frameshift mutations are the most 
common causes to type 3 VWD, but also large deletions and missense mutations can do so.   
1.3.4 Acquired VWD 
Acquired VWD syndrome (AVWS) refers to defects in VWF concentration, structure or 
function not inherited but that are consequences of other medical disorder. The VWF multimers 
distribution may be normal, but often shows a reduction in the large multimers. The main 
AVWS causes are autoimmune clearance or inhibition of VWF, increased shear-induced VWF 
proteolysis or increased bindings between VWF and platelets or collagen.     
 1.4 Diagnosis and VWD detection 
The VWD diagnosis and the correct types detection are obtained taking into consideration the 
personal bleeding history of the patient with some information about the presence of a family 
history of bleeding events and the laboratory tests to detect quantitative o qualitative VWF 
deficiency.  Because of the numerous VWD types and the high heterogeneity that characterized 
VWD, an algorithm reported in Figure 1.6 was proposed to prevent the misdiagnosis. 
The initial clinical assessment is focus on his personal and family history of excessive bleeding 
disorders. There must be identify the bleeding sites, severity, duration and type of injury 
associated to bleeding. This first evaluation is challenging, in fact mild bleeding disorder are 
very common in healthy populations. In addition, VWD cause bleeding, but bleeding is not 
specific related to VWD. A positive family history is useful to identify persons who are likely 
to have VWD, but in cases of mild VWD, such family history could not be present.  
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Figure 1.1. Diagnosis algorithm used for VWD diagnosis (Adapted from N.H.B.L.I., 2007). 
The common initial haemostasis laboratory tests are: 
 Complete blood count (CBC); a test that determine the concentrations of the main cells 
presents in the blood (platelets, white blood cells, red blood cells); 
 Prothrombin time (PT); a test that measures the time needed to cloth formation by the 
extrinsic pathway of haemostasis that involves factor I, II, V, VII and X. 
 Partial tromboplastin Time (PTT); a tests that measures the time needed to cloth 
formation by the intrinsic pathway; 
 Fibrinogen; a test used to determine the fibrinogen concentration. Fibrinogen is 
enzymatically converted to fibrin by thrombin; 
 Thrombin Time (TT); a test that measures the clotting time and indicates the conversion 
of fibrinogen to fibrin. 
If one or more of these tests results abnormal, a more specific set of tests is needed to diagnosis 
the VWD. The initial tests for VWD includes measures of the VWF amount present in plasma, 
the function of VWF protein and the VWF ability to maintain FVIII in blood circulation.  
In order to obtain a diagnosis and detection of VWD sub-types an important test is the DDAVP. 
DDAVP test involves the vasopressin (1-deamino-8D-arginine vasopressin) administration and 
the collection of blood samples following a precise time schedule (0, 15, 30, 60, 120, 180, 240, 
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360, 480, 1440 min). Vasopressin induce the VWF release stored in the Weibel-Palade bodies, 
which is then exposed to the proteolytic actions of ultralarge multimers and then undergoes to 
its clearance. Each blood sample is then subjected to VWD specialized laboratory tests. 
1.4.1 Clinical tests 
VWF:Ag measures the concentration of VWF protein presents in plasma and it is expressed in 
International Units (IU) per volume. The method used is based on enzyme-linked 
immunosorbent assay (ELISA). The reference curve is construct using a pool of normal washed 
platelets (N.H.L.B.I., 2007). 
VWF:RCo measures the VWF ability to interacts with normal platelets. Ristocetin antibiotic 
causes the binds between VWF and platelets resulting in platelets clumps that is then removed 
from circulation. Ristocetin is a valid test for VWD but it has been removed because it caused 
thrombocytopenia (N.H.L.B.I., 2007). 
VWF:CB measures the VWF ability to binds with collagen and it is expressed in International 
Units (IU) per volume. The collagen binding assay is dependent on VWF multimeric size, with 
the larger multimers that binds more than the smaller. The VWF:CB is used for both VWD 
detection and VWD discrimination among VWD types (N.H.L.B.I., 2007). 
VWF:FVIII binding measures the VWF ability to binds factor VIII. VWF bind FVIII so to 
prevent its cleavage. It is used to distinguish between VWD and haemophilia A, and to diagnose 
type 2N VWD (N.H.L.B.I., 2007).  
Platelet VWF measures the VWF concentration in platelets. Platelet VWF is a measure of the 
VWF synthesis quality; it is accepted that platelet VWF is synthetized in much the same way 
than the plasma VWF, but it is more resistant to the ADAMST13 proteolytic action and so it 
shows an enhanced haemostatic action (Casonato, 2016).   
DNA sequencing is a DNA test. For VWD type 2, the cDNA mutations are directly related to 
each subtypes (2M, 2B, 2N, 2A), while for VWD type 1 this test could be useless. In most 
person who have type 1 VWD, the genetic mutations have not been established (N.H.B.L.I., 
2007). DNA sequencing is not widely available. 
1.4.2 Model-based VWD Characterization and diagnosis  
Because of the difficulties related to the VWD diagnosis and characterization discussed in the 
previous chapter several pharmacokinetic models have been proposed. The model proposed by 
Galvanin (2014) aims of describing the phenomena that occurs after the DDAVP 
administration;  from the VWF multimers release from the subendothelium, passing through 
Chapter 1 
 
14 
 
their proteolysis to their clearance from the circulating blood plasma. A model able to describe 
the patient’s biological pathway in a reliable way is a powerful tool in the VWD diagnosis and 
characterization; furthermore it may permit the identification of a more effective therapies 
providing a better life for the patient and saving medical efforts.  
Recent works (Ferrari et al, 2018) proposed a simplified Galvanin pharmacokinetic model 
which is able to predict the VWF:Ag and VWF:CB levels. The model identifiability involves 
the DDAVP test (as will be discuss in the next Chapter) with a precise time schedule sampling 
activity. The VWD pharmacokinetic model is tested through its identifiability from 
experimental measures and assessing its ability to represent the predicted variables. A 
pharmacokinetic model that well represent the phenomena involved permits to obtain some 
information about the system described that are not directly shown in experimental measures 
and allows a deeper process knowledge, which can be used both to facilitate the medical work 
and to improve the patient life. Appling an advance model-based technique it is possible to 
reduce the DDAVP time required to model identification, while through some pharmacokinetic 
indexes is possible to well characterized each subject allowing the development of a model-
based technique to assist the medical decision making task in the diagnosis fields (Castaldello 
et al, 2017).  
1.5 Thesis objective 
The VWD type 1 is the most common VWD, covering about the 65% of the total VWD cases 
and because of its high heterogeneity is the most difficult to diagnose. In particular, the diagnose 
of mild type 1 VWD is very challenging and also the genetic test is often useless. The simplified 
pharmacokinetic model proposed by Ferrari et al (2018), showed good results in terms of 
identifiability and predicted responses and it was tested on the VWD type 2A, 2B and Vicenza. 
The first goal of this thesis work is to test the simplified PK model on the VWD type 1 obtaining 
a pharmacokinetic characterization of the entire pull of patients. The characterization can be 
made through the model parameters or using some PK indexes; both will be described in the 
next Chapter. 
The information given by the PK model will then be used to propose a procedure for VWD 
diagnosis. 
 
   
 
  
Chapter 2 
Mathematical methods 
Pharmacokinetic models have been developed to describe the VWF processes that occur in the 
organism following the DDAVP administration. In this chapter, the PK model used is described 
and its mathematical formulation will be provided. A mathematical background for the 
parameters estimation activity will be given and some tests used in this Thesis to assess the 
estimation quality will be discussed. The development of a model-based classification protocol 
involves some data-analysis and pattern recognition techniques; in this chapter the main 
techniques used will be discussed and their mathematical formulation provided.  
2.1 Simplified Pharmacokinetic model of von Willebrand disease  
After the vasopressin (DDAVP) administration, three principal phenomena occur involving the 
VWF multimers: 
1.  Release of VWF multimers; 
2.  VWF proteolysis to smaller multimers by ADAMST13 action; 
3.  Clearance of VWF (independently of multimers size). 
Several pharmacokinetic models has been proposed (Galvanin et al, 2014) to describe the 
courses of plasma VWF:Ag and VWF:CB levels after the vasopressin administration. 
A reliable pharmacokinetic model of VWD should have these features (Galvanin et al, 2014): 
 It should represent the real physiological pathways involved in the time evolution of 
VWF concentration; 
 its parameters should be easily identifiable from clinical tests available; 
 it should be sufficient flexible to well-describe the single patient; 
 it should represent the multimers distribution in time. 
The model adopted in this Thesis work is the one proposed by Ferrari et al, (2018) which is a 
simplification of the model originally developed by Galvanin et al (2014). 
The model, sketched in Figure 2.1, comprises two compartment and it is designed based on the 
following assumptions (Ferrari et al, 2018): 
 at the basal state only high (H) and low (L) molecular weight multimers are presents; 
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 the release of ultra-large (UL) and high (H) molecular weight multimers is consequence 
of vasopressin administration;  
 the elimination is considered independent of the multimers size; 
 VWF:Ag measures the total amount of VWF, comprising UL, H, and L multimers; 
 VWF:CB measures the amount of UL and H multimers size. 
 
 
 
 
 
 
 
 
 
 
 
 
 
The model is described by the following set of differential and algebraic equations: 
 
𝑑𝑥𝑈𝐿+𝐻
𝑑𝑡
= 𝑘0𝐷𝑒
−𝑘0(𝑡−𝑡𝑚𝑎𝑥) − 𝑘1(𝑥
𝑈𝐿+𝐻 − 𝑥𝑏
𝑈𝐿+𝐻) − 𝑘𝑒(𝑥
𝑈𝐿+𝐻 − 𝑥𝑏
𝑈𝐿+𝐻) , (2.1) 
 
𝑑𝑥𝐿
𝑑𝑡
= 𝑘1 (𝑥
𝑈𝐿+𝐻 − 𝑥𝑏
𝑈𝐿+𝐻) − 𝑘𝑒 (𝑥
𝐿 − 𝑥𝑏
𝐿) , (2.2) 
where 𝑥𝑈𝐿+𝐻 and 𝑥𝐿 are the number of UL+H and L multimers units respectively and the 
subscript b stands for the basal condition. The amount of VWF released is represented by the 
D parameter while 𝑘0 is the parameter that quantifies the release rate. 𝑘1 and 𝑘𝑒 are respectively 
the proteolysis and elimination rate. 𝑡𝑚𝑎𝑥, called lag time, is the time of the maximum response. 
The VWF:Ag and VWF:CB concentration measurements are respectively related to the 
multimers units as:  
 𝑦𝐴𝑔 =
𝑥𝑈𝐿+𝐻+𝑥𝐿
𝑉𝑑
 , (2.3) 
 𝑦𝐶𝐵 =
𝑥𝑈𝐿+𝐻
𝑉𝑑
 ,  (2.4) 
where the distribution volume 𝑉𝑑 is approximated using the body weight BW following the 
equation (Menache et al., 1996): 
 𝑉𝑑 = 0.4 𝐵𝑊 .  (2.5) 
Figure 2.1. Pharmacokinetic model structure with the two 
compartments and the location of VWF:Ag and VWF:CB 
measurements (Adapted from Ferrari et al, 2018). 
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In order to take into account the different affinity of multimers to collagen between different 
VWD type, a correction factor k is introduced: 
 𝑦𝐶𝐵
′
= 𝑘 𝑦𝐶𝐵  
𝑦𝑏
𝐴𝑔
𝑦𝑏
𝐶𝐵 . (2.6) 
The conversion from multimers units to concentration is expressed in the following equations: 
 𝑥𝑏
𝑈𝐿+𝐻 = 𝑦𝑏
𝐶𝐵 𝑉𝑑  , (2.7) 
 𝑥𝑏
𝐿 = 𝑦𝑏
𝐴𝑔 𝑉𝑑 − 𝑥𝑏
𝑈𝐿+𝐻 . (2.8) 
The parameters set θ [theta] that has to be estimated comprise seven parameters obtained after 
a riparametrization: 
 𝜽 = [𝑘0, 𝑘1, 𝑘𝑒 , 𝐷 𝑡𝑚𝑎𝑥⁄ , 𝑘, 𝑦𝑏
𝐶𝐵, 𝑡𝑚𝑎𝑥]. (2.9) 
The parameters estimated set permit to define some pharmacokinetic indexes which are 
commonly used to the subjects characterization as the Q amount of VWF multimers released, 
the CL blood volume treated for unit of time and weight and the R ratio between the VWF:CB 
and VWF:Ag at the basal state. These PK are defined by the following equations: 
 𝑄𝑟𝑒
𝑈𝐿+𝐻 = 𝑄𝑟𝑒 = 
1
𝐵𝑊
∫ 𝑘0 𝐷 𝑒
−𝑘0 (𝑡−𝑡𝑚𝑎𝑥) 𝑑𝑡
𝜏
0
 ; (2.10) 
 𝐶𝐿𝑈𝐿+𝐻 = 𝑉𝑑 𝑘𝑒  
1
𝐵𝑊
  ; (2.11) 
 𝑅 = 
𝑣𝑊𝐹:𝐶𝐵𝑏
𝑣𝑊𝐹:𝐴𝑔𝑏
  ;  (2.12) 
where the subscript re stand for released and τ is the experiment time.  
2.1.1 Parameters estimation 
A model M can be represented by a system of differential and algebraic equations (DAEs) as: 
 𝑀: {
𝑓(?̇?(𝑡), 𝒙(𝑡), 𝒖(𝑡), 𝒘, ?̂?, 𝑡) = 0
?̂?(𝑡) = 𝒉(𝒙(𝑡))
 , (2.13) 
where: 
 x(t) ϵ ℜ𝑁𝑥 is the vector of time-dependent state variables; 
 ?̇?(t) ϵ ℜ𝑁𝑥 is the derivative vector of time-dependent state variables; 
 𝒖(𝑡) 𝜖 ℜ𝑁𝑢 is the set of the time-dependent control variables; 
 𝒘(𝑡) 𝜖 ℜ𝑁𝑤 is the vector of time-invariant control variables; 
 ?̂? 𝜖 ℜ𝑁𝜃 is the set of unknown parameters to be estimated; 
 𝑡 is the time of the experiment; 
 
Chapter 2 
 
 
18 
 
 ?̂?(𝑡) 𝜖 ℜ𝑁𝑦 is the vector of predicted variables. 
When a model has been selected among a set of candidate, its identification is due to the 
parameters identification through some available experimental measures. The aims of the 
parameters estimation activity are to obtain the parameters values that maximise the model 
capability to predict the measured response and to achieve a satisfactory statistically parameters 
estimation.  
An estimator Φ𝑃𝐸 can be defined as: 
 ?̂? =  Φ𝑃𝐸(𝒚): ℜ𝑁𝑦 → ℜ𝑁𝜃 (2.14) 
where ?̂? is the set of estimated parameters.  
The quality of an estimator is assessed by the quality of the estimated parameters in terms of 
accuracy and precision. Estimated parameters accuracy is related to the nearness to its true 
value; in general this feature cannot be verified because the true values of the model parameters 
are unknown. Parameters precision is achieved with the minimum dispersion around the 
estimated values. 
A satisfactory estimation result should be a vector of parameters having the minimum variance 
and providing the minimum deviation between the predicted response ?̂? and the measured 
variables y. This can be obtain by minimizing the residuals quantity 𝑟𝑖𝑗 defined as: 
 𝑟𝑖𝑗 = ||𝑦𝑖(𝑡𝑗) − ?̂?𝑖(𝑡𝑗)||                𝑖 = 1,… ,𝑁𝑦,  𝑗 = 1,… ,𝑁𝑠𝑝, (2.15) 
where t is the time of the experimental measure, 𝑁𝑦 is the response number and 𝑁𝑠𝑝 is the 
experimental measures number.  
The measurement values are affected by measurement uncertainty and for this reason, an 
associated probability distribution function (PDF) should be defined. The most widespread 
univariate PDF is called normal distribution function and is describe by the following equation: 
 𝑝(𝑥) =
1
√2 𝜋 𝜎2
 𝑒−
1
2
(
𝑥−𝜇
𝜎
)
2
 , (2.16)  
where μ is the mean and σ is the standard deviation.   
If the model used to describe the system is correct and only measurement errors affects the 
system responses, it is reasonable to model the residues PDF as normally distributed with zero 
mean and a certain standard deviation 𝜎𝑖𝑗. Considering that the residues PDF is function of the 
set of parameter θ since ?̂?𝑖(𝜃), the joint probability function, assuming the residuals as 
uncorrelated, is defined by the likelihood function: 
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 𝐿(𝜽) =  ∏ ∏
1
√2 𝜋 𝜎𝑖𝑗
2
𝑁𝑚
𝑗=1
𝑁𝑒𝑥𝑝
𝑖=1  𝑒
−
1
2
(
𝑥−𝜇
𝜎𝑖𝑗
)
2
 . (2.17) 
The minimization of the residual from equation (2.15) can be reformulate through the likelihood 
maximization, thus the parameters estimation problem can be write as (Bard, 1974): 
 𝑚𝑎𝑥𝜃{𝐿(𝜽)} = 𝑚𝑎𝑥𝜽 {∏ ∏
1
√2 𝜋 𝜎𝑖𝑗
2
𝑁𝑚
𝑗=1
𝑁𝑒𝑥𝑝
𝑖=1  𝑒
−
1
2
(
𝑥−𝜇
𝜎𝑖𝑗
)
2
}. (2.18) 
The use of equation (2.18) approach rather than equation (2.15) has many advantages: it takes 
into account the measures uncertainly and also permits to obtain some a-posteriori statistics 
useful to assess the quality of the estimation. 
To achieve the parameters estimation using the maximum likelihood method, the following 
elements are required (Galvanin, 2010): 
 a model with its initial condition; 
 an initial guess for the entire set of parameter; 
 a set of design vectors that define the experimental setting; 
 a y set of experimental data;  
 information about the measurement system expressed by the variance-covariance matrix 
𝜮𝑦. 
If no information about 𝜮𝑦 is given, is possible to use a variance model in the form of the 
following equation: 
 𝜎𝑦𝑗 = 𝜔𝑗
2(?̂?𝑗
2)𝛾𝑖   (2.19) 
where the γ and ω are the two model parameters which are defined depending on the variance 
model type applied. The possible values are summarized in Table 2.1. 
 
Table 2.1 Variance model parameters values depending on the variance model choose. 
Expected variance model γ ω 
Constant variance 0 Fixed a-priori or estimated 
Constant relative variance 1 Fixed a-priori or estimated 
Heteroschedastic Fixed a-priori or estimated Fixed a-priori or estimated 
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2.1.2 Information content analysis 
When a model has been selected among a set of candidate, its identification can be divided in 
two steps: the a priori identifiablility and the a posteriori identifiability. The a priori 
identifiability activity aims of verifying if the model parameters can be estimated in a noise-
free and disturbance-free conditions. 
The a priori identifiability condition is verified if given two different parameters set θ and 𝜽∗ 
the following condition: 
 𝑀(𝜽) =  𝑀(𝜽∗)  ⇒  𝜽 = 𝜽∗  (2.20) 
is verified and so the model responses are the same if the parameters set are equal.  If equation 
(2.20) is always satisfy the model is Structurally Globally identifiable (SGI), while it is 
Structurally Locally identifiable (SLI) if there exist a θ neighbour that satisfy condition (2.20). 
A priori identifiability is a necessary condition to guarantee successful parameters estimation 
using noise-affected real data which characterized the a posteriori identifiability. 
Sensitivity analysis is the study of how a variation in one parameter affects the model outputs 
and it is used to assess the a posteriori identifiability.  
Local and global sensitivity analysis have been proposed, for attaining two goals: 
 to detect the most influential parameters affecting the system responses; 
 to analyse the information behaviour for a given set of experimental conditions. 
Sensitivity analysis is carry out by perturbing the PK parameters (1%) and observing how it 
affects the model responses. Mathematically this can be expressed as: 
 𝑞𝑖
𝐴𝑔 =
?̂?𝐴𝑔(𝜃𝑖
′)−?̂?𝐴𝑔(𝜃𝑖)
𝜃𝑖
′−𝜃𝑖
       𝑖 = 1,… ,𝑁𝜃     (2.21)  
 𝑞𝑖
𝐶𝐵 =
?̂?𝐶𝐵(𝜃𝑖
′)−?̂?𝐶𝐵(𝜃𝑖)
𝜃𝑖
′−𝜃𝑖
       𝑖 = 1,… ,𝑁𝜃 (2.22) 
where 𝜃𝑖
′ and 𝜃𝑖 represent the perturbed and original set of parameters while 𝑁𝜃 is the number 
of model parameters. 
Let 𝑁𝑦 number of model responses, the 𝑁𝑦 ⨯ 𝑁𝜃 matrix of local sensitivities Q is represented 
by the following equation: 
 𝑸(𝑡) = [
𝑞1,1(𝑡) ⋯ 𝑞1,𝑁𝜃(𝑡)
⋮ ⋱ ⋮
𝑞𝑁𝑦,1(𝑡) ⋯ 𝑞𝑁𝑦,𝑁𝜃(𝑡)
] =
[
 
 
 
 
𝜕?̂?1(𝑡)
𝜕𝜃1
⋯
𝜕?̂?1(𝑡)
𝜕𝜃𝑁𝜃
⋮ ⋱ ⋮
𝜕?̂?𝑁𝑦(𝑡)
𝜕𝜃1
⋯
𝜕?̂?𝑁𝑦(𝑡)
𝜕𝜃𝑁𝜃 ]
 
 
 
 
  (2.23) 
which can be evaluated for each r-th measured response at each sampling time through the 
𝑛𝑠𝑝 ⨯ 𝑁𝜃 matrix 𝑸𝑟 represented in equation (2.24). 
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 𝑸𝑟 =
[
 
 
 
 
  
𝜕𝑦𝑟
𝜕𝜃𝑖
|
𝑡1
⋯
𝜕𝑦𝑟
𝜕𝜃𝑁𝑝
|
𝑡1
⋮ ⋱ ⋮
𝜕𝑦𝑟
𝜕𝜃𝑖
|
𝑡𝑛𝑠𝑝
⋯
𝜕𝑦𝑟
𝜕𝜃𝑁𝑝
|
𝑡𝑛𝑠𝑝]
 
 
 
 
 
 . (2.24) 
The analysis of time profile of local sensitivities shows the dynamic behavior of the parametric 
system, providing useful information about the parameters estimation. Considering a single 
response model with four parameters, looking at the sensitivities profile shown in Figure 2.2, it 
is possible to note that parameters 𝑞11 and 𝑞14 shows great sensitivity on the model response, 
while for parameter 𝑞12 the sensitivity is null. About the parameters estimation activity it is 
reasonable to think that parameter 𝑞12 will be hardly identifiable since it does not affects the 
model response, while parameters 𝑞11 and 𝑞14 seem to be easily identifiable but they are 
strongly anti-correlated. 
 
The dynamic sensitivity matrix is strictly correlated to the information foreseen by the model 
identification. For a multiple input, multiple output (MIMO) dynamic system the information 
carried by the model can be defined as: 
 𝑰(𝜽, 𝑡) = [𝑸′ 𝑇(𝑡) 𝜮𝑦
−1 𝑸𝑇(𝑡)] (2.25) 
Where 𝜮𝑦 is the 𝑁𝑦 ⨯ 𝑁𝑦 variance-covariance measurement matrix and I is the information 
matrix. Under the Zullo hypothesis (Zullo,1991) an information matrix discrete form can be 
formulated as: 
 𝑯𝜃(𝜽,𝝋) =  ∑ ∑ ∑ ?̃?𝑖𝑗|𝑘  𝑸𝑖|𝑘
𝑇  𝑸𝑗|𝑘
𝑁𝑦
𝑗=1  +  𝑯𝜃
0𝑁𝑦
𝑖=1
𝑁𝑠𝑝
𝑘=1  . (2.26) 
Figure 2.2 Dynamic sensitivities profile for a model with four parameters 
and a single response (Galvanin, 2010)  
 
Chapter 2 
 
 
22 
 
The estimated model parameters variance-covariance matrix 𝑽𝜃 is the inverse of the dynamic 
information matrix 𝑯𝜃: 
 𝑽𝜃(𝜽,𝝋) =  [𝑯𝜃(𝜽,𝝋)]
−1 = [∑ ∑ ?̃?𝑖𝑗  𝑸𝑖
𝑇 𝑸𝑗
𝑁𝑦
𝑗=1  
𝑁𝑦
𝑖=1 ]
−1
. (2.27) 
Model parameters variance-covariance matrix 𝑽𝜃 is used to assess the parameters quality. 
2.1.3 Estimation quality  
The parameters estimation activity aims of solving model equations (2.13) minimizing the 
objective function (2.15); statistical tests are essential to verify the estimated parameters 
quality.  
A satisfactory parameters estimation should have the following features (Emery, 2001): 
 accuracy: the estimate parameters has to capture the information embedded by the 
experimental measures, rejecting the noise and disturbances effects; 
 precision: the parameters uncertainty has to be minimized. 
The parameters estimated precision is strictly related to the parameters variance-covariance 
matrix defined by equation (2.27). 
If the parameters are assumed to be normally distributed, the t-test is a powerful test to 
understand if parameters are well estimated or not. Defining the confidence interval as: 
 𝑘𝑖 = 𝑡 (
1−𝛼
2
, 𝑛𝑠𝑝 𝑁𝑦 − 𝑁𝜃) √𝜈𝑖𝑖 ,     𝑖 = 1,… ,𝑁𝜃, (2.28)  
where t is the upper  (1 − 𝛼) 2⁄  critical value for a t-distribution with (𝑛𝑠𝑝 𝑁𝑦 − 𝑁𝜃) degrees 
of freedom, 𝑛𝑠𝑝 is the number of experimental points, 𝑁𝑦 is the number of model response and 
𝑁𝜃 is the number of model parameters. For a (1 − 𝛼) = 95 % confidence level, the confidence 
interval can be approximated by the following equation: 
 𝑘𝑖
95% = 2 √𝜈𝑖𝑖 ,     𝑖 = 1,… ,𝑁𝜃. (2.29) 
For system without high correlation between model parameters, once the variance-covariance 
matrix of model parameters 𝑽𝜃 is known, it is possible to carry out a t-test. The t-values are 
evaluated as:  
 𝑡𝑖 = 
?̂?𝑖
√𝜈𝑖𝑖
 ,     𝑖 = 1,… ,𝑁𝜃, (2.30) 
where 𝜈𝑖𝑖 is the i-th diagonal element of 𝑽𝜃. The t-values obtained from equation (2.30) are 
compared with respect to the reference t-values considering a t-distribution with (𝑛𝑠𝑝 𝑁𝑦 − 𝑁𝜃) 
degrees of freedom. High t-values usually mean that parameters are estimated with high 
confidence and high precision. When the system shows high correlation between model 
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parameters, it is necessary to take into account also the parameters covariance, thus not only 
the diagonal elements of matrix 𝑽𝜃. 
To verify the proper residual minimization, the lack-of-fit-test (𝜒2-test) can be performed 
considering the sum of the weighted residuals: 
𝑆𝑊𝑅 =  ∑ [(𝑦𝑖 − ?̂?𝑖)𝛴𝑦
−1(𝑦𝑖 − ?̂?𝑖)]
𝑛𝑠𝑝
𝑖=1 . (2.31) 
In the lack-of-fit-test the SWR value is compared with a reference value from a 𝜒2 distribution 
considering (𝑛𝑠𝑝 𝑁𝑦 − 𝑁𝜃) degrees of freedom. If 𝑆𝑊𝑅 <  𝜒
𝑟𝑖𝑓 the experimental data fitting 
is efficient and it is reasonable to consider the model as a reliable representation of the physical 
system. Because the assumption made in § 2.1.1 about the Gaussian distribution of 
measurements, the residual distribution should be confirmed by the “whiteness test”.  
2.2 Principal component analysis 
Principal component analysis (PCA) is a mathematical and statistical technique used to 
formulate an empirical model derived from data that allows estimating one or more system 
properties from measurements. 
The idea behind the PCA is to compress and then extract, in a proper way, the data available, 
making possible to (Wise and Gallagher, 1996): 
 use only relevant data-embedded information, avoiding redundant information which 
are useless; 
 describe how the system variables changes to each other’s; 
 averaging the data measurement, avoiding to describe the noise measurement.  
Mathematically, the PCA relies on a decomposition of the original data set variance-covariance 
matrix. Let X the 𝑚 × 𝑛 matrix where the rows represents the samples while columns 
corresponds to variables. To avoid errors associated to different unit dimension between each 
variable, the data are pre-processed; each columns are mean-centered (i.e. the columns mean is 
subtracted to each column elements) and scaled to its variance (i.e. each column elements is 
divided by the columns variance).  
The PCA decompose the data matrix X as: 
 𝑿 = 𝒕1𝒑1
𝑇 + 𝒕2𝒑2
𝑇+. . . +𝒕𝑘𝒑𝑘
𝑇 + 𝑬 (2.32) 
where the 𝒕𝑖 vectors are known as scores while 𝒑𝑖 vectors are known as loadings. In equation 
(2.32), k is a number that necessarily must be less than or equal to the smaller dimension of X. 
The scores vectors contain the information of how the samples are related to each other, while 
loadings describe how the variables are related to each other.  
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For a given and auto-scaled matrix X, its covariance matrix can be defined as: 
 𝑐𝑜𝑣(𝑿) =
𝑿𝑇𝑿
𝑚−1
 .  (2.33) 
The 𝒑𝑖 vectors are the eigenvectors of the covariance matrix and by its definition: 
 𝑐𝑜𝑣(𝑿)𝒑𝑖 = 𝜆𝑖𝒑𝑖 , (2.34) 
where 𝜆𝑖 is the eigenvalue associated to its eigenvector. It is possible to think of 𝜆𝑖 as the amount 
of covariance described by the associated eigenvector. In the decomposition activity the 𝒑𝑖 and 
𝒕𝑖 pairs are in descending order of related 𝜆𝑖, so the first dimension describes the major 
variability. The k number of dimension used to describe the original data set can be chosen 
through the cumulative variance captured.  
The scores vectors are obtained from the original data-set by the following equation: 
 𝒕𝑖 =  𝑿𝒑𝑖  (2.35) 
The scores vectors 𝒕𝑖 are orthogonal (i.e. 𝒕𝑖
𝑇𝒕𝑗 = 0 𝑓𝑜𝑟 𝑖 ≠ 𝑗) to each other and form an 
orthogonal base, while the 𝒑𝑖 vectors are orthonormal (i.e. 𝒑𝑖
𝑇𝒑𝑗 = 0 𝑓𝑜𝑟 𝑖 ≠ 𝑗, 𝒑𝑖
𝑇𝒑𝑗 =
1 𝑓𝑜𝑟 𝑖 = 𝑗 ). Collecting the 𝒕𝑖 vectors into the T matrix and the 𝒑𝑖 vectors into the P matrix it 
is possible to represent the PCA decomposition as: 
 𝑿 = 𝑻𝑷𝑇 + 𝑬, 𝑴 = 𝑻𝑷𝑇 , (2.36) 
where the product 𝑻𝑷𝑇 represent the original data-set described by the new model and is 
function of the k number of selected dimension. Equations (2.32) and (2.36), thus the X matrix 
decomposition are shown in Figure 2.3 where the score and loading scores are highlighted. 
 
Figure 2.3 Representation of data matrix X decomposition as sum of 𝑀𝑖 matrices and residual 
E. The 𝑀𝑖 matrices are the products of the score and loading vectors product. (Adapted from 
Esbensen, Geladi, 2009). 
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The PCA permits a new base identification through scores vectors; it is possible to think of a 
new k-dimensional fictitious space where the original data-set is projected (Figure 2.4) (Geladi, 
2009).  
2.3 Supervised pattern recognition  
The supervised pattern recognition problem can be represent as the wish of fit a model that 
properly relates the response to the observed predictors measurements (James et al, 2013) with 
the aim to accurately predicts the response for future observations. In contrast, in unsupervised 
pattern recognition problem there is no associated response to the observed measurements. 
When quantitative variables are used as response ones, it is common refer to as a regression 
problem, while if the response variables are qualitative it is refer to as classification problems. 
There are many classification techniques, also called classifiers, and all needs an observations 
training set which is used to build the classifier model. The classifier aim is to perform a correct 
classification not only in the training set, but also on the set not used during the training phase. 
To achieve this feature, the model is subject to the validation phase that can be done using an 
external data-set, or an internal data-set of the training set, which is referred to as cross-
validation. 
2.3.1 Support vector machine 
In a p-dimensional space, let define the hyperplane as a flat affine subspace of p-1 dimension 
which mathematically is represented by the following equation (James et al, 2013): 
 𝛽0 + 𝛽1𝑋1 + 𝛽2𝑋2+. . . +𝛽𝑝𝑋𝑝 = 0   (2.37) 
Figure 2.4 Representation of a projection of three dimensional space data 
in a two dimensional space detected by the two Principal Component. 
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Given a 𝑛 × 𝑝 data matrix 𝑿 representing n training observations of p-dimensional predictors 
  𝑿 = (
𝑥11 ⋯ 𝑥𝑛1
⋮ ⋱ ⋮
𝑥1𝑝 ⋯ 𝑥𝑛𝑝
) ,  (2.38) 
and assuming that each observation falls into two classes represented as 𝑦1, … , 𝑦𝑛 𝜖{−1,+1} , 
it is possible to construct a hyperplane on the form of equation (2.34) that perfectly separates 
the observations accordingly to their labels. Such hyperplane, for each i-observation has the 
following properties: 
 𝛽0 + 𝛽1𝑥𝑖1 + 𝛽2𝑥𝑖2+. . . +𝛽𝑝𝑥𝑖𝑝 > 0  𝑖𝑓 𝑦𝑖 = 1, (2.39) 
 𝛽0 + 𝛽1𝑥𝑖1 + 𝛽2𝑥𝑖2+. . . +𝛽𝑝𝑥𝑖𝑝 < 0  𝑖𝑓 𝑦𝑖 = −1. (2.40) 
It is possible to think of the quantity on the right side of inequalities (2.36) and (2.37) as a 
measure of the distance of each point from the hyperplane. 
The concept expressed by the equations (2.39) and (2.40) can be equivalently wrote as 
 (𝛽0 + 𝛽1𝑥𝑖1 + 𝛽2𝑥𝑖2+. . . +𝛽𝑝𝑥𝑖𝑝) 𝑦𝑖 > 0 . (2.41) 
Generally, if our data are perfectly separable, there will be exists an infinite number of 
hyperplanes that separates the two classes (Figure 2.5) 
 
Computing the perpendicular distance from each training observation to the hyperplane, and 
defining the margin as the minimum distance from observations to the hyperplane, the optimal 
separating plane is the one that maximize such distance. Such hyperplane is the solution to the 
following optimization problem: 
Figure 2.5 Three different hyperplane in a two-dimensional space that 
perfectly separates the observations belonging to two different classes, 
indicated respectively with circles and x. 
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 max
𝛽0,𝛽1,…,𝛽p
𝑀,  (2.42) 
 ∑ 𝛽𝑗
2 = 1,𝑝𝑗=1   (2.43) 
 (𝛽0 + 𝛽1𝑥𝑖1 + 𝛽2𝑥𝑖2+. . . +𝛽𝑝𝑥𝑖𝑝) 𝑦𝑖 > 𝑀   ⩝ 𝑖 = 1,… , 𝑛 , (2.44) 
where M represent the margin to be maximized by changing the 𝛽p hyperplane parameters. 
Equation (2.44) guarantees that each observation lies on the correct side of the hyperplane. 
Equation (2.43) impose that perpendicular distance from each observation to the hyperplane 
can be simply calculated by: 
 (𝛽0 + 𝛽1𝑥𝑖1 + 𝛽2𝑥𝑖2+. . . +𝛽𝑝𝑥𝑖𝑝) 𝑦𝑖 (2.45) 
Ensuring, together with equation (2.44) that each observation is on the correct side of the 
hyperplane and at least at a distance M from it.  
The maximal margin hyperplane obtained from the equations (2.42), (2.43) and (2.44) 
resolution is function of only a small part of the training set. The observation that are 
fundamental for the problem resolution are called support vectors (Figure 2.6). 
 
Figure 2.6 Maximal margin hyperplane representation (solid line) in a two-class problem (circles and pluses). The margin is 
the distance between the hyperplane and the dashed lines, which is detected by the support vectors shown as filled circles and 
filled square for each class, respectively.   
The maximal margin hyperplane represented by equations (2.42), (2.43) and (2.44) is very 
sensitive to the observations and in some cases is desirable to have a classifier that does not 
perfectly separates the two classes in favour of the following features: 
 greater robustness to individual observations; 
 better classification of most of the training observations. 
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In order to obtain these features on the classifier method, the cost parameter (C) is added to the 
system through equation (2.44) that becomes: 
 (𝛽0 + 𝛽1𝑥𝑖1 + 𝛽2𝑥𝑖2+. . . +𝛽𝑝𝑥𝑖𝑝) 𝑦𝑖 > 𝑀 (1 − 𝜖𝑖)    ⩝ 𝑖 = 1,… , 𝑛 , (2.46) 
with the following constraints 
𝜖𝑖 ≥ 0, ∑ 𝜖𝑖
𝑛
𝑖=1 ≤ 𝐶, (2.47) 
where the 𝜖𝑖 are slack variables that indicate where individual observations are located with 
respect to the hyperplane or the margin following this criterion: 
 if 𝜖𝑖 = 0 the i-th observation lies on the wright side of the margin; 
 if 𝜖𝑖 > 0 the i-th observation is on the wright side of hyperplane but violates the margin; 
 if 𝜖𝑖 > 1 the i-th observation is on the wrong side of hyperplane. 
The C parameter bounds the sum of the slack variables and it represents the margin violations 
that can be tolerated; as C increase the margin violations will become more allowed, 
consequently the margin will be widen, in contrast low C values means wider and rarely 
violated margin (Figure 2.7). 
2.3.2 Kernel functions 
The introduction of kernel function in the maximal margin hyperplane problem permits to 
identify non-linear boundary between the two classes. 
The solution of the optimization problem formulated by equations (2.42), (2.43), (2.46) and 
(2.47) involves the inner products of the observations vectors, which can be formulated as: 
 〈𝑥𝑖 , 𝑥𝑗〉 = ∑ 𝑥𝑖𝑦 𝑥𝑗𝑦
𝑝
𝑦=1  . (2.48) 
Figure 2.7 Representation of margin with respect to the cost paramenters. Low cost values produces wide margine (on the 
left). High cost values produces widen margin which are more violated (on the  right). 
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The linear support vector classifier can be represented as: 
 𝑓(𝑥) = 𝛽0 + ∑ 𝛼𝑖 〈𝑥, 𝑥𝑖〉,
𝑛
𝑖=1  (2.49) 
where there are n parameters 𝛼𝑖, one for each training observation. As discussed earlier, only 
for the support vectors the 𝛼𝑖 parameters are non-zero and this simplified the solution of the 
problem.  
Generalization of the inner product can be written as 𝐾(𝑥𝑖, 𝑥𝑗), where K is some function called 
kernel, which quantifies the similarity between two observations.  
Defining a kernel function in the support vector machine problem is possible to pass from the 
original input p-dimensional space to an enlarged dimensional space, where the samples are 
projected and the problem presented by equations (2.42), (2.43), (2.46) and (2.47) is solved 
(Figure 2.8) (Xu et al, 2006).  
 
Only certain kernels functions can be employed and are (Xu et al, 2006):  
 Polynomial function (PF) 
 𝐾(𝑥𝑖 , 𝑥𝑗) =  (𝛼𝑥𝑖
𝑇𝑥𝑗 + 𝑏)
𝑐
 (2.50) 
 Radial basis function (RBF) 
 𝐾(𝑥𝑖 , 𝑥𝑗) = exp
−‖𝑥𝑖−𝑥𝑗‖
2
2𝜎2
 ; (2.51) 
 Sigmoidal function (SF) 
𝐾(𝑥𝑖, 𝑥𝑗) = tanh(𝛼𝑥𝑖
𝑇𝑥𝑗 + 𝑏). (2.52) 
Each kernel has a set of parameters that has to be tuned; the radial-basis-function, in particular, 
has a single parameter σ that represent the radial width which make it particularly widespread. 
Instead of use the σ parameter, it is common to use γ, which is related to σ following the 
relations: 
Figure 2.8 Representation of the support vector machine problem with non-linear kernel function. (Adapted from Xu, 2006). 
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 𝛾 =
1
2𝜎2
 .   (2.53) 
The effects on boundaries with respects to the 𝛾 parameter are shown in Figure 2.9 ; as 𝛾 
increases the boundaries complexity increases, too. 
2.3.3 Model validation 
Acting on the 𝛾 parameter, the kernel trick allows the definition of complex boundaries able to 
perfectly separates each observation belonging to different classes, but the model complexity 
must be controlled in favour of model robustness and also in order to avoid overfitting 
problems. The support vector machine optimization problem must be solved searching for a 
good compromise between the penalty error C and the kernel function parameters. 
The solution is obtained through a cross-validation activity and the optimal set of parameters is 
the one that produce the lower misclassification error. Cross-validation is done splitting the n 
initial data set number of observations in s smaller datasets; some sets are used to train the 
model while the others to test its performance. 
There are several type of cross validation, the most widespread are: 
 venetian blinds, where the tests set is determined selecting every s-th observation in the 
original data-set; 
 random subsets, where the test sets are determined randomly trough a selection of n/s 
observations, providing no presence of a single observation in more than one test set; 
 leave-one-out, where single observation is used as test set. 
The misclassification error is reported as a ratio between the number of misclassified subjects 
and the total subjects number classified. The misclassification error can be represented through 
Figure 6.9 Representation of support vector machine problem boundaries with respect to the RBF kernel function 
parameter 𝛾. Low values of 𝛾 gives smoother boundaries (on the left). High 𝛾 values gives more contorted boundaries 
(on the right). 
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the confusion matrix, which is reported in Figure (2.10), where misclassification error is 
reported for each class analysed. 
 
In Figure 2.10, n is the number of subjects; the first subscript indicates the model predicted 
class, while the second subscript indicates the real subject class. 
2.3.4 Probability estimation 
There are two possible ways to assign an unknown observation to a class: 
 based on the sign of the equation (2.39); 
 based on the associated probability to belong of each class. 
The probability distribution function is calculating through a parametric model fitting. Looking 
at the SVM problem resolution it is clear that some points (observation) are forced to be on the 
margin (support vector) and have all the same distance from the hyperplane. This fact involves 
a discontinuity in the class-conditional densities. 
Because the class-conditional densities behaviour, the suggested probability distribution 
function (PDF) is the sigmoid form with two parameters on the form: 
 𝑃(𝑦 = 1|𝑓) =
1
1+𝑒𝑥𝑝 (𝐴 𝑓 + 𝐵)
 ,  (2.51) 
where A and B are the sigmoid parameters. 
The use of the entire SVM training set to train the sigmoid is to be avoided because it leads to 
a biased PDF model. The method used for deriving an unbiased training set is the cross-
validation, which involves the training set splitting in three parts; in three-fold cross-validation, 
the training set is split into three parts and on two out of three parts the SVM model is trained, 
Figure 2.10 Confusion matrix representation for a 
two class classification problem. 
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while the remaining fold is used to evaluate the 𝑓𝑖, which is used to compute the probability 
distribution function expressed by equation (2.51). The union of all three sets of 𝑓𝑖 form the 
entire sigmoid training set (Platt, 1999).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
  
Chapter 3 
Model-based type 1 VWD 
characterization 
In this chapter, the VWD average subjects pharmacokinetic model parameters are compared to 
each other and discussed. The PK model parameters and PK indexes for type 1 VWD are 
compared to the healthy classes and the other VWD types and finally an intra-type 1 VWD 
categorization based on the mutation type are analysed through the PK model indexes.  
3.1 Preliminary average VWD type 1 subject analysis  
 A critical point in the parameter estimation activity is the choice of initial guess for the 
parameters set. For this purpose, a fictitious VWD type 1 average subject has been created 
averaging the VWF:Ag and VWF:CB values at each sampling time for the entire VWD type 1 
data-set available. The VWD type 1 data set has been given from the collaboration with the 
hospital of Padua.  
The average VWD subject VWF:Ag and VWF:CB profiles for each VWD type is reported in 
Figure (3.1a) and Figure (3.1b). The fictitious VWF measurements, accordingly to Galvanin et 
al (2014), are assumed with a standard deviation 𝜎𝐴𝑔 = 𝜎𝐶𝐵 = 2 𝐼𝑈/𝑑𝐿.  
Looking at the average VWF:Ag levels for the different VWD types (Figure 3.1a), the type 1 
VWD subject is similar to the 2A and 2B average subjects and, with respect the healthy type, 
is more similar to the healthy O blood group type. The VWD type 1 average subject shows 
VWF:CB levels that are more similar to the healthy class O blood group than to those of the 
VWD type 2A and 2B.  
Since the average heathy O blood group subject is the more similar to the VWD type 1 average 
subject, its set of PK model parameters has been used as initial guess to the average type 1 
VWD subject parameters estimation. Subsequently the average VWD type 1 parameters set will 
be used as initial guess for the parameters estimation activity for each VWD type 1 subject.  
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The parameters estimation of the pharmacokinetic model presented in § 2.1 is carried out using 
the gPROMS® v4.1.0 software. To facilitate the convergence the parameters estimation activity 
is split in three steps: 
 step 0: all seven parameters 𝑘0, 𝑘1, 𝑘𝑒 , 𝐷, 𝑘, 𝑦𝑏
𝐶𝐵, 𝐷 𝑡𝑚𝑎𝑥⁄  are free to vary; 
 step 1: the corrective parameters 𝑘, 𝑦𝑏
𝐶𝐵and the 𝐷 𝑡𝑚𝑎𝑥⁄  parameter are set at the values 
estimated in the previous step, while the kinetic parameters 𝑘0, 𝑘1, 𝑘𝑒 , 𝐷 are free to vary; 
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Figure 3.1 a) VWF:Ag levels for each average VWD categories and healthy classes. 
b) VWF:CB levels for each average VWD categories and healthy classes.  
(a) 
(b) 
 
Model-based type 1 VWD characterization 
 
 
35 
 
 step 2: the kinetic parameters 𝑘0, 𝑘1, 𝑘𝑒 , 𝐷 are set at the values estimated in the previous 
step, while the corrective parameters 𝑘 𝑎𝑛𝑑 𝑦𝑏
𝐶𝐵 are left free to vary. 
Step 1 and step 2 are repeated until the estimated values do not change significantly. The 
𝐷 𝑡𝑚𝑎𝑥⁄  parameter is kept constant for all the steps subsequently to step 0 since it is easily 
identifiable; this simplifies the parameter estimation process. 
Because of the numerical issue that could arise due to the different scale associated of each 
parameter, the parameters estimation has been carried out considering a normalized set of 
parameters defined by the following equation: 
𝛩𝑖 =
?̂?𝑖
𝜇𝑖
 ,     𝑖 = 1,… ,𝑁𝜃 , (3.1) 
where μ is the parameter initial guess value, 𝜃 is the original parameter and 𝛩 is the normalized 
parameter. When the parameters are normalized, their sensitivities analysis measure the relative 
response variations, which are easily comparable to each other.   
The parameter set for each average VWD type subjects are reported in Table 3.1. The type 1 
VWD average subject shows a parameter set quite similar to the average healthy with O blood 
group, except for the release parameter D which is lower. Vicenza and 2B shows a higher 
proteolysis rate than the average VWD type 1.  
 
Table 3.1 Pharmacokinetic models parameters set for each average VWD type subject (Castaldello, 2016). 
  
 
 
 
 
 
 
 
 
 
Average VWD type subjects cannot be considered a good representation of the entire VWD 
type because of the high variability (Taverna, 2017), anyway the parameters set reported in 
Table 3.1 suggest that the PK model is capable to represent the different VWD types. The high 
Vicenza and 2B proteolysis rate means a fast reduction in high VWF multimers weight and a 
reduced VWF haemostatic ability. The low release parameter means a quantitative reduction in 
VWF, which characterized the VWD type 1.      
Parameter HnonO HO 2B Vic Type 1 
𝒌𝟎 [𝒉
−𝟏] 0.0285 0.0264 0.0136 0.0423 0.0280 
𝒌𝟏 [𝒉
−𝟏] 0.00014 0.00033 0.0021 0.0013 0.0004 
𝒌𝒆 [𝒉
−𝟏] 0.00069 0.00136 0.00369 0.00983 0.0014 
D [IU] 167.631 140.511 193.638 198.938 86.4874 
k [-] 0.9681 0.9952 0.2231  0.7427 0.9418 
𝒚𝒃
𝑪𝑩 [𝑰𝑼 𝒅𝑳⁄ ] 84.670 50.675 29.464 5.6121 33.0138 
𝑫 𝒕𝒎𝒂𝒙⁄  [IU/h] 1.5436 1.2669 0.85196 2.9623 0.7582 
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The average VWD type 1 subject parameter estimation is satisfactory in terms of precision; in 
Table 3.2 and Table 3.3, respectively, the parameters estimation statistics are reported for step 
1 and step 2. All the parameters satisfy the t-test and the 𝑘1 parameter shows the lower t-value 
with respect to the other parameter.  
 
Table 3.2 Parameters estimation results for step 1. The t-test and chi-squared results are reported. 
 
 
Table 3.3 Parameters estimation results for step 2. The t-test and chi-squared results are reported. 
 
The 𝜒2 test is not satisfied, in fact 𝜒2 < SWR. Looking at the predicted VWF:Ag and VWF:CB 
profiles with respect the experimental values (Figure 3.2), the model response well captures the 
general experimental behaviour.      
 Initial Guess Final Value 95% t-value Dev.st. Reference t-
value (95%) 
Weighted 
Residual 
𝝌𝟐 (95%) 
 
𝒌𝟎 1.0557 1.0557 11.69 0.04261  
1.74561 
 
58.4853 
 
26.2962 𝒌𝟏 1.08965 1.08965 2.639 0.1948 
𝒌𝒆 1.05573 1.05573 8.024 0.06206 
D 0.612245 0.612245 13.91 0.02076 
 Initial Guess Final Value 95% t-value Dev.st. Reference t-
value (95%) 
Weighted 
Residual 
𝝌𝟐 (95%) 
𝒌 0.954804 0.954788 13.58 0.03333  
1.73975 
 
58.4853 
 
27.5871 𝒚𝒃
𝑪𝑩 0.660656 0.660641 8.584 0.03647 
𝑫
𝒕𝒎𝒂𝒙⁄
 0.592401 0.592373 115.4 0.002433 
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The sensitivity analysis (Figure 3.3a) shows that the 𝑘1 and 𝑦𝑏
𝐶𝐵 parameters do not affects 
VWF:Ag measurements; 𝑘1 do not affect the VWF:Ag levels because of the model formulation 
while 𝑦𝑏
𝐶𝐵 is related to VWF:CB measure only. The sensitivity analysis suggests that the 𝑘1 and 
𝑦𝑏
𝐶𝐵parameters cannot be identified from the VWF:Ag measures but they are exclusively related 
to the VWF:CB measures. Looking at the sensitivity analysis with respect to the VWF:CB 
model response (Figure 3.3b), the 𝑘1 parameter may exhibit some identifiability issues since it 
is not significantly affected by the VWF:CB model response.  
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Figure 3.2 a) Experimental and model predicted VWF:Ag levels for the average VWD type 1 subject. b) Experimental and 
model predicted VWF:CB levels for the average VWD type 1 subject. 
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Figure 3.3 a) Representation of VWF:Ag model response sensitivity to the entire parameters set. b) Representation of VWF:CB 
model response sensitivity to the entire parameters set. 
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A heteroscedastic variance model presented in §2.11 has been used to quantify the VWD type 
1 group variability. The models parameters are obtained by the minimization of the sum of 
squared residual and the results are reported in Table 3.4 for each VWD category.   
 
Table 3.4 Heteroscedastic variance model parameters.  
Response Parameter H0 Hnon0 2B Vic Type 1 
VWF:Ag ω 7.917 20.589 4.418 1.252 1.180 
γ 0.325 0.210 0.397 0.762 0.7893 
VWF:CB ω 2.436 17.090 0.128 2.028 0.9680 
γ 0.578 0.258 1.533 0.653 0.8477 
 
At the maximum VWF:AG and VWF:CB levels for average type 1 subject, which are 
respectively about 110 IU/dL and 135 IU/dL, the model standard deviation is respectively 58 
IU/dL and 62 IU/dL.  
 
3.2 Model based VWD type 1 characterization 
Using the average VWD type 1 subject parameters reported in §3.1 as initial guess, the model 
parameter estimation for each VWD type 1 subject has been carried out. The estimated PK 
parameters are averaged and compared with respect the averaged parameters for each VWD 
type. The healthy classes, which are divided respectively in O and non-O blood group, are used 
as control groups. The group variance are compared with the Tukey-Kramer test assuming a 
studentized range distribution. The null hypothesis is that the two groups analysed can be 
considered different. The null hypothesis is rejected if: 
|𝑡| =
|𝑦𝑖−𝑦𝑗|
√𝑀𝑆𝐸(
1
𝑛𝑖
+
1
𝑛𝑗
)
> 
1
√2
 𝑞𝑎,𝑘,𝑁−𝑘, (3.2) 
Where 𝑞𝑎,𝑘,𝑁−𝑘 is the upper 100*(1-α)th percentile of a studentized range distribution, k is the 
number of groups and N is the total number of observations. The value N-k represents the 
degrees of freedom. The chosen p-value used in the Tukey-Kramer test is 0.05. 
 
Model-based type 1 VWD characterization 
 
 
39 
 
VWD type 1 shows an average elimination rate higher than both the healthy classes even if 
statistically can not be considered different from healthy O blood group class while is different 
from healthy non-O blood group class (Figure 3.4a). Vicenza VWD type shows the highest 
average elimination rate 𝑘𝑒 while VWD type 2B has a reduced average 𝑘𝑒 with respect the 
Vicenza but higher than the healthy classes and type 1 VWD. Both Vicenza and 2B type are 
statistically different from healthy and type 1 classes. 
 
 
High elimination rate means a fast reduction in both UL+H and L PK model compartments. A 
fast UL+H VWF multimers weight elimination involves a reduction in the VWF 
haemostatically action which characterized the Vicenza and 2B VWD type.  
Type 2B and Vicenza shows an enhance proteolysis rate 𝑘1 (Figure 3.4b), which means a fast 
reduction in the high VWF multimers weight; even if the standard deviation is high, the 𝑘1 for 
these classes can be considered statistically different from both the healthy and type 1 classes. 
VWD type 1 has an average 𝑘1 comparable to the healthy classes while, for the healthy classes, 
subjects with non O blood group shows a reduce average proteolysis rate. Statistically the 
healthy and type 1 VWD classes cannot be considered independent. The results shown in Figure 
3.4b do not consider some subjects affected by VWD type 1 because of the difficulties related 
to the 𝑘1 identification.  
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Figure 3.4 a) Comparison between the estimate elimination rate for each VWD type and healthy class. b)  Comparison between 
the estimate proteolysis rate for each VWD type and healthy class. Asterisks indicate the parameters significantly different 
from control groups (p < 0.005). 
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Average 𝑘0 for all the VWD type do not differs significantly, except for the 2B type which 
shows a lower average release rate. By the way, statistically none of the classes can be 
considered different from each other (Figure 3.5a).  
The average release parameter D (Figure 3.5b) for VWD type 1 is lower than both the healthy 
classes but its high variability make it not statistically different from healthy classes. The 2B 
and Vicenza types show high D parameter, but only the subjects affected by VWD type Vicenza 
can be considered statistically different from the healthy classes. 𝑘0 and D are two parameters 
that identify the VWF release which can not be measured and their effect on the  phenomena 
representation is not always clearly distinguishable; the amount of VWF released, instead, takes 
into account both the parameters and the combined effects. The average amount of VWD 
released for VWD type 1 is slightly reduced with respect the healthy class O blood group which 
is lower than the healthy class non O blood group (Figure 3.6a). The 2B type has the highest 
average 𝑄𝑟𝑒 , while the Vicenza group is slightly higher than the VWD type 1. Statistically, 
only VWD type 2B can be considered different from the healthy classes, while the type 1 VWD 
cannot be considered different from type Vicenza. This result suggests that the Vicenza type 
could be classified under VWD type 1 (N.H.B.L.I., 2007).   
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Figure 3.5 a) Comparison between the estimate release rate for each VWD type and healthy class. b)  Comparison between 
the estimate release parameter for each VWD type and healthy class. Asterisks indicate the parameters significantly different 
from control groups (p < 0.005). 
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VWD type 1 shows an average clearance higher than both the healthy classes; the healthy  O 
blood group has an enhanced clearance with respect the non-O. Statistically the VWD type 1 
category can be considered different from healthy non-O group but not from healthy O group. 
Both the 2B and Vicenza type have a high clearance with respect the healthy classes (Figure 
3.6b).   
Looking at the ratio (R) at the basal condition between the VWF:CB and VWF:Ag levels 
(Figure 3.6c) the VWD type 1 shows an average value similar to the other classes except for 
type 2B which shows the lowest average ratio. 
The model-based results, in terms of amount of VWF released and clearance, confirm the 
knowledge found in literature (Sadler, 2014). VWD type 1 shows a modest decrease amount of 
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VWF and an increased clearance with respect to the healthy subjects. With respect the other 
VWD types, type 1 is the most similar to the healthy class with O blood group, confirming the 
difficulties related to its detection and correct diagnosis.  
In Figure 3.7 the combination of amount of VWF released and clearance is reported for each 
healthy and affected by VWD subject classified for VWD categories. All the VWD Vicenza 
subjects shows a higher clearance than the others categories. Some subjects of type 2B VWD 
shows reduced clearance, which could be considered similar to some type 1 VWD and healthy 
O blood group subjects. Healthy subjects are well characterized based on the blood group; non-
O blood group subjects shows a lower value of clearance with than healthy O blood group.  
 
 
The region that identify the type 1 VWD is quite overlapped with the healthy classes; subjects 
with non-O blood group are ore only partially overlapped, while O blood group subjects are not 
clearly distinguishable basing on the proposed PK indexes.   
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Figure 3.7 Combined model-based pharmacokinetic parameters amount of VWF released and clearance 
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3.3 Intra VWD type 1 characterization 
The subjects affected by VWD type 1 are divided into categories depending on the mutation 
type in the VWF gene. The data has been collected for the three categories: missense mutation, 
nonsense mutation and no mutation.  
The elimination rate 𝑘𝑒 is increased for all the VWD type 1 categories (Figure 3.8a). Healthy 
O group shows an increased clearance with respect the heathy non O blood group. The subjects 
without mutation shows the highest average clearance and it is the only category that can be 
considered statistically different from both the healthy classes. The missense and nonsense 
group statistically differs from healthy non O group but not from healthy O group.      
 
Looking at the average 𝑘1 for each class (Figure 3.8b), the missense mutation group shows the 
highest value; because of its high variability it can be considered statistically different from 
healthy non-O blood group but not from the healthy O blood group. Healthy O group, in fact, 
shows a higher average proteolysis rate than the healthy non-O blood group. Nonsense mutation 
and no mutation categories have an average 𝑘1 similar to the healthy O blood group but 
statistically are not different. The results shown in Figure 3.7b did not take into account the 
entire VWD type 1 dataset because of the difficulties related to the proteolysis rate estimation. 
Looking at both average 𝑘0 and average D for each VWD type 1 categories (Figure 3.9), there 
is no appreciable differences between healthy and VWD type 1 classes. Furthermore, none of 
the VWD categories can be considered statistically different from the healthy classes. 
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Figure 3.8 a) Comparison between the estimate elimination rate for each type 1 VWD mutation categories and healthy class. 
b) Comparison between the estimate proteolysis rate for each type 1 VWD mutation categories and healthy class. Asterisks 
indicate the parameters significantly different from control groups (p < 0.005). 
*
 
(a) (b) 
 
Chapter 3 
 
 
44 
 
 
 
The average amount of VWF released for the missense and nonsense mutation groups is lower 
than the healthy groups (Figure 3.10a). Subjects with no VWF gene mutation shows an average 
VWF release, which is slightly higher than the healthy O class and lower than the healthy non-
O class. Looking at the variability intra-group, none of the VWD type 1 categories can be 
considered different from the healthy O blood group, while the two mutation groups are 
statistically different from healthy non-O blood group (Figure 3.10a).  
The subjects with VWF gene mutation shows a higher clearance than the healthy classes but 
slightly lower than the subjects without mutations; because of their variability the VWD type 1 
categories cannot be considered statistically different from each other. Furthermore, none of 
the VWD type 1 categories can be considered statistically different from healthy O class.  The 
no mutation category shows the highest average clearance and is the only VWD type 1 category 
statistically different from the healthy non-O blood group class (Figure 3.10b).  
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The subjects without mutation shows the highest average velocity of release which can be 
considered statistically different from subjects with gene mutation. The missense and nonsense 
categories shows an average velocity of release lower than the healthy classes, even if it cannot 
be considered statistically different because of the high variability (Figure 3.10c).    
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Looking at Figure 3.11 where the combination of the amount of VWF released and the clearance 
is reported for each VWD type 1 subject distinguished by genetically categorization, it is 
possible to recognise three main clusters: 
1. a cluster characterized by a very low amount of VWF released (<15 IU/kg) (red ellipse) 
comprising subjects 6, 8, 17, 19, 33 and 48. In the literature this cluster is referred to as 
severe type 1 (Sadler, 2003), (Casonato et al, 2016); 
2. a cluster characterized by a slightly reduced amount of VWF released and a reasonable 
increased clearance (black ellipse), which comprise mainly subjects carrying missense and 
nonsense mutation and subject 27, which does not carry any mutation;   
3. a cluster characterized by an increased amount of VWF released and increased clearance 
which (blu ellipse) mainly include subjects without mutation and some subjects carrying 
missense mutations.  
Cluster 2 and cluster 3 together identify the mild type 1 category.  
 
 
The high variability associated to each VWD type 1 categories is clearly visible in Figure 3.11; 
the subjects that carry nonsense mutation are present in both mild and severe VWD type 1 
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Figure 3.11 Combined model-based pharmacokinetic parameters amount of VWF released and 
clearance for the entire type 1 VWD set of subjects. The three main clusters are highlighted.   
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categories depending on the specific mutation. Subjects 17 and 19 carry a double VWF gene 
mutation while subject 48 carry a nonsense homozygote mutation.  
The subjects carrying missense mutation are mainly in the mild type 1 clusters except subject 
6 which shows a gene deletion and subject 8. Some subjects carrying missense mutation are 
quite similar in terms of amount of VWF release and clearance to subjects without VWF gene 
mutation; subjects 47 and 29 carry the C1130F mutation and shows an enhanced clearance. The 
high clearance shows by the PK model is confirmed by the literature (Sadler, 2014). Subjects 
4, 26 and 36 carry the P2063S missense VWF gene mutation but its correlation with the VWD 
is not clear (Hampshire, 2013); so it is reasonable to think of this subjects more similar to the 
subjects without mutation.      
 
 
Looking at the combined measures of amount of VWF released and the basal state ratio between 
VWF:CB and VWF:Ag levels (Figure 3.12) it is possible to recognise the same three clusters 
identify by the combination of amount of VWF released and clearance. An important 
overlapping between the mild type 1 clusters is present; subjects 10, 14 and 27, which did not 
carry any mutation shows an amount of VWF released and a ratio similar to the missense and 
nonsense mutation subjects. Subjects 29 and 47 are the only subjects present in the data set, 
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Figure 3.12 Combined model-based pharmacokinetic parameters amount of VWF released and VWF:CB 
and VWF:Ag ratio at the basal state for the entire type 1 VWD set of subjects. 
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which bring the C1130F VWF gene mutation. They are comprised in the mild type 1 VWD but 
show a reduced basal ratio suggesting a partial reduction in the VWF high multimers weight. 
Figure 3.13 shows how type 1 VWD subjects and healthy subjects are located with respect to 
the clearance and amount of VWF released. A partial overlapping between the region identified 
by type 1 subjects and the one identified by healthy non-O blood group subjects is present; 
subjects 32 and 43 do not carry any VWF gene mutation, while subject 18 carries a nonsense 
mutation. 
 
 
Subjects with severe type 1 VWD shows an amount of VWF released lower than the healthy 
subjects and subjects 8 and 33 also exhibit a higher clearance. The subjects with VWF gene 
mutation belonging to the mild type 1 VWD show quite the same PK indexes as the healthy O 
blood group subjects. Looking at the subjects without VWF gene mutation, a partial 
overlapping with both healthy O e non-O blood groups is present.
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Figure 3.13 Combined model-based pharmacokinetic parameters amount of VWF released clearance for 
the entire type 1 VWD and healthy set of subjects. 
   
 
  
Chapter 4 
Model-based type 1 VWD diagnosis 
In this chapter, the proposed algorithm to obtain the type 1 VWD diagnosis is presented. The 
data and the data analysis used in the algorithm are described and each algorithm step is 
validated through a cross-validation method; the results in terms of performances are reported 
and discussed.  
4.1 Preliminary raw experimental data analysis  
In Chapter 3 the pharmacokinetic model results demonstrated the PK model difficulty to 
describe the differences between healthy and affected subjects. A PCA was carried out on the 
entire autoscaled dataset of experimental VWF:Ag and VWF:CB levels during the DDAVP test 
considering all the VWD types and the healthy classes. The variability captured by the firsts 
two PC for the entire dataset is reported in Figure 4.1. The cumulative variance captured is the 
93.11% of the total. 
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Figure 4.1 Representation of the firsts two principal component of a PCA carried out on the 
experimental VWF:Ag and  VWF:CB measures considering all the VWD subtypes and healthy 
subjects. 
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Type 1 VWD subjects show VWF:Ag and VWF:CB levels between the healthy O blood group 
and Vicenza VWD type, while the 2B group is quite separated from all the other categories. 
Looking at the raw experimental VWF:Ag and VWF:CB measures, subjects 6, 8, 17, 19 and 
48, which are affected by severe type 1 VWD,  show VWF levels that are similar to the Vicenza 
type while the model-based PK indexes shown in previous chapter seems able to better capture 
the differences between the two categories in terms of clearance and R. 
Focusing only for the type 1 VWD affected subjects, a PCA is carried out only on the raw 
experimental data belonging to type 1 VWD and the two healthy classes, and the variability 
captured by the firsts two PC is reported in Figure 4.2. The subjects belonging to the healthy 
class are 38, while the subjects affected by type 1 VWD are 51. The cumulative variance 
captured is the 93.88% of the total. 
A partial overlapping is present between type 1 VWD subjects and healthy O blood group 
subjects. The subjects with VWF:Ag and VWF:CB levels more similar to the healthy classes 
are mainly subjects with P2062S VWF gene mutation. Subjects 2, 4, 26 and 36 carry the P2063S 
mutation, subject 43 do not carry any VWF gene mutation while subjects 18 and 49 both carry 
nonsense mutation. 
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Figure 4.2 Representation of the firsts two principal component of a PCA, which capture the 93.88 
% of the total variability, carried out on the experimental VWF:Ag and  VWF:CB measures 
considering healthy and type 1 VWD subjects. 
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Subjects 18 and 49, even if they both carry a nonsense mutation, which usually correspond to 
a reduction in VWF levels, show normal VWF levels. In these subjects, in fact, the disease is 
extremely mild, did not affect their lifestyle, and no particular bleeding disorder were observed.    
4.2 Proposed model-based algorithm for type 1 VWD diagnosis  
If a subject results positive at the diagnosis algorithm presented in §1.4, specialized VWD 
studies are required. In Figure 4.3 is reported the proposed algorithm which, using already used 
specialized VWD clinical tests, aims to assist the medical work during the long procedure to 
obtain a type 1 VWD diagnosis.  
The results shown in § 3 suggest that type 2B ad Vicenza are easily diagnosed by already 
developed classification method proposed by Castaldello et al (2017). Furthermore, the 
methodology used to type 2B and Vicenza classification do not interfere with algorithm 
proposed for type 1 VWD classification. 
 
 
 
 
 
Figure 4.3 Scheme representing the proposed algorithm to obtain a type 1 VWD diagnosis depending on the presence of VWF 
gene mutation or not. 
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The proposed algorithm uses the VWF:Ag and VWF:CB levels from the DDAVP test to 
classify a subject as affected by VWD type 1 or healthy by support vector machine (SVM) 
classifier. Other methods (PLS-DA, KNN) were applied and compared but gives worst results.  
The second steps aims of recognising if a subject has a VWF gene mutation or not. This second 
classification is done using the informative pharmacokinetic indexes discussed in Chapter £ and 
the platelet VWF measurement. The PK indexes used are the amount of VWF released, the 
clearance and the ratio. 
4.3 Healthy- type 1 VWD classification 
Data are organized in a matrix where rows represent the subjects and columns represent the 
VWF:Ag and VWF:CB levels during the DDAVP test. A PCA is carried out on the organized 
data and the variance captured by each PC is reported in Table 4.1. 
 
Table 4.1 Variance captured by each PC in the PCA on the DDAVP VWF levels. 
PC1 PC2 PC3 PC4 
90.68 % 3.20 % 1.92 % 1.57 % 
 
A SVM classifier model with radial basis kernel function has been trained using the first three 
PC of the PCA, which capture a cumulative variance equal to the 95.80 % of the total. The γ 
and C SVM-classifier parameters are obtained through the leave-one-out cross validation 
method. The parameters that best perform in the validation activity are 𝛾 =  0.2570 and 𝐶 =
19.95. The SVM classifier model is defined by 31 support vectors, 13 belonging to the type 1 
VWD class and 18 support vectors for the healthy class. 
The trained SVM model features and performances are summarized in Table 4.2 where SV 
indicate the number of support vector and ER the error rate in cross validation. The total error 
rate is calculated by the following equation (Ballabio and Todeschini, 2009): 
        𝐸𝑅𝑡𝑜𝑡
𝐶𝑉 = 1 −
∑ 𝑛𝑖𝑖
𝐺
1=1
𝑛
; (4.1) 
where CV stand for cross validation activity, G is the number of groups and 𝑛𝑖𝑖 is the ii-th 
element of the confusion matrix. For the single group, the error rate is calculated considering 
the 𝑛𝑔 number of subjects which belong to that group; the subscript indicate the group by which 
each index is related to. 
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Table 4.2 Summarized SVM classifier features and performances. 
γ C 𝑺𝑽𝒕𝒐𝒕 𝑺𝑽𝒕𝒚𝒑𝒆 𝟏 𝑺𝑽𝑯𝒆𝒂𝒍𝒕𝒉𝒚 𝑬𝑹𝒕𝒐𝒕
𝑪𝑽  𝑬𝑹𝒕𝒚𝒑𝒆 𝟏
𝑪𝑽  𝑬𝑹𝑯𝒆𝒂𝒍𝒕𝒉𝒚
𝑪𝑽  
0.2570 19.95 31 13 18 0.1125 0.1190 0.1043 
 
The total percentage misclassification error in cross validation is 11.25 %, but some subjects 
are wrongly classified even in the calibrated model with the optimized parameters. Subjects 36 
and 49 are wrongly classified in the calibrated model; their VWF:Ag and VWF:CB levels are 
reported respectively in Figure 4.4a and Figure 4.4b, comparing their profiles with the average 
type 1 VWD and healthy blood group O subject. Both subjects shows VWF:Ag and VWF:CB 
levels more similar to the average healthy blood group O than the average type 1 VWD. Subject 
36 carry the P2063S VWF gene mutation while subject 49 has a nonsense VWF gene mutation 
but he shows normal VWF levels. 
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In cross-validation phase, the subjects wrongly classified are subjects 18, 32 and 43 and their 
VWF:Ag and VWF:CB levels are reported respectively in Figure 4.5a and Figure 4.5b. Subject 
18 carry a nonsense mutation while subject 32 and 43 have no VWF gene mutation.  
To make the SVM classifier more robust, a threshold probability value is applied to assign a 
class to a single subject. Two threshold probability values have to be chosen, one for the 
classification in the type 1 VWD class and one for defining the healthy class. The best couple 
of thresholds value are obtained through a leave-one-out method where the subject used as test 
can be classified as: 
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Figure 4.4 a) Experimental  VWF:Ag measurement for subjects 36 and 49. b) Experimental  VWF:CB measurement for 
subjects 36 and 49. 
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Figure 4.5 a) Experimental  VWF:Ag measurement for subjects 18, 32 and 43. b) Experimental  VWF:CB measurement for 
subjects 18, 32 and 43. 
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 type 1 VWD if its associate probability is higher than the threshold value chosen for 
the type 1 VWD assignment;   
 healthy if its associate probability is higher than the threshold value chosen for the 
healthy assignment;  
 type 1 VWD unclassified if the subject is classified as type 1 VWD but its associated 
probability is lower than the threshold value chosen for the type 1 VWD assignment; 
 healthy unclassified if the subject is classified as healthy but its associated probability 
is lower than the threshold value chosen for the healthy assignment. 
The confusion matrix obtainable with the previous classification is reported in Table 4.3. 
 
Table 4.3 Representation of the confusion matrix obtainable form the application of thresold probability for the class 
assignment. 
 Predicted Class 
  Healthy Type 1 VWD Unclassified 
 
Real Class 
Healthy Healthy Classified Healthy misclassified Healthy unclassified 
VWD1 VWD1 misclassified VWD1 classified VWD1 unclassified 
Unclassified - - - 
. 
 
The thresholds probability values aims to minimize the misclassified subjects. With the 
proposed classification criteria as the threshold values increase, the misclassification error rate 
decreases and the unclassified subjects increase. By looking at Figure 4.6a and Figure 4.6b, 
where the misclassification error rate and the unclassified percentage are reported in function 
of the thresholds value for each class, it can be observed that by increasing the threshold values 
the misclassification error decreases slower than the increase in the percentage of unclassified 
subjects. Consequently, the rate of subject correctly classified decreases.  
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The error rate and the unclassified subjects percentage for the thresholds values comprised 
between 0.550 and 0.650 are reported respectively in Table 4.4 and Table 4.5 for the type 1 
VWD class and in Table 4.6 and Table 4.7 for the healthy class.  
 
Table 4.4 Misclassified error rate for type 1 VWD subjects depending on threshold probability values comprises between 0.550 
and 0.650. Bold value corresponds to the chosen pair of threshold probability value. 
  Healthy probability threshold 
 
Type 1 
VWD 
probability 
threshold 
 0.550 0.575 0.600 0.625 0.650 
0.550 0.1190 0.1190 0.1190 0.1190 0.0952 
0.575 0.1190 0.1190 0.1190 0.1190 0.1190 
0.600 0.1190 0.1190 0.1190 0.1190 0.0952 
0.625 0.1190 0.1190 0.1190 0.0952 0.1190 
0.650 0.1190 0.1190 0.0952 0.0952 0.0952 
 
 
 
 
 
 
 
 
Figure 4.6  a) Representation of the error rate of the SVM classifier depending on the threshold probability value for each 
class assignment. b) Representation of the percentage of unclassified subjects depending on the threshold probability value for 
each class assignment. 
(a) 
 
(b) 
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Table 4.5 Unclassified rate for type 1 VWD subjects depending on threshold probability values comprises between 0.550 and 
0.650. Bold value corresponds to the chosen pair of threshold probability value. 
  Healthy probability threshold 
 
Type 1 
VWD 
probability 
threshold 
 0.550 0.575 0.600 0.625 0.650 
0.550 0.0238 0.0238 0.0238 0 0.0476 
0.575 0.0238 0.0238 0.0476 0.0238 0.0238 
0.600 0.0238 0.0238 0.0238 0.0238 0.0476 
0.625 0.0714 0.0714 0.0714 0.0476 0.0476 
0.650 0.0714 0.0714 0.0952 0.1190 0.0714 
 
 
Table 4.6 Misclassified error rate for healthy subjects depending on threshold probability values comprises between 0.550 and 
0.650. Bold value corresponds to the chosen pair of threshold probability value. 
  Healthy probability threshold 
 
Type 1 
VWD 
probability 
threshold 
 0.550 0.575 0.600 0.625 0.650 
0.550 0.0750 0.1000 0.0750 0.0750 0.1000 
0.575 0.0750 0.0750 0.0750 0.0750 0.0750 
0.600 0.0500 0.0750 0.0500 0.0750 0.0750 
0.625 0.0500 0.0500 0.0500 0.0750 0.0750 
0.650 0.0500 0.0500 0.0500 0.0500 0.0500 
 
 
 
Table 4.7 Unclassified rate for healthy subjects depending on threshold probability values comprises between 0.550 and 0.650. 
Bold value corresponds to the chosen pair of threshold probability value. 
  Healthy probability threshold 
 
Type 1 
VWD 
probability 
threshold 
 0.550 0.575 0.600 0.625 0.650 
0.550 0.1000 0.1000 0.2000 0.2000 0.2250 
0.575 0.0750 0.1500 0.1500 0.1500 0.2250 
0.600 0.1250 0.1250 0.1500 0.2000 0.2250 
0.625 0.1250 0.1250 0.2000 0.2250 0.2250 
0.650 0.1500 0.1500 0.2000 0.2250 0.2500 
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Table 4.8 Total misclassified rate depending on threshold probability values comprises between 0.550 and 0.650. Bold value 
corresponds to the chosen pair of threshold probability value. 
  Healthy probability threshold 
 
Type 1 
VWD 
probability 
threshold 
 0.550 0.575 0.600 0.625 0.650 
0.550 0.1000 0.1125 0.1000 0.1000 0.1000 
0.575 0.1000 0.1000 0.1000 0.1000 0.1000 
0.600 0.0875 0.1000 0.0875 0.1000 0.0875 
0.625 0.0875 0.0875 0.0875 0.0875 0.1000 
0.650 0.0875 0.0875 0.0750 0.0750 0.0750 
 
 
Table 4.9 Total unclassified rate depending on threshold probability values comprises between 0.550 and 0.650. Bold value 
corresponds to the chosen pair of threshold probability value. 
  Healthy probability threshold 
 
Type 1 
VWD 
probability 
threshold 
 0.550 0.575 0.600 0.625 0.650 
0.550 0.6000 0.6000 0.0719 0.0950 0.1319 
0.575 0.0481 0.0838 0.1081 0.0838 0.1194 
0.600 0.0719 0.0719 0.0838 0.1075 0.1319 
0.625 0.0969 0.0969 0.1325 0.1319 0.1319 
0.650 0.1087 0.1087 0.1450 0.1694 0.1563 
 
Table 4.8 and Table 4.9 report the total misclassification error rate and the total percentage of 
subjects unclassified for the threshold values comprised between 0.550 and 0.650. The lower 
total misclassification error rate corresponds to the higher unclassified percentage; the threshold 
probability values are chosen searching for the lower misclassification error with a reasonable 
unclassified percentage. With a probability threshold of 0.650 for the healthy class assignment 
and 0.600 for the type 1 VWD assignment, the misclassification error rate is 0.0875 and the 
unclassified rate is 0.1319. The SVM classifier shows an error rate for type 1 VWD class 
assignment equal to 0.0952 (Table 4.4), which is slightly higher than the one for the healthy 
class equal to 0.0750 (Table 4.6). The unclassified rates are quite different for the two classes; 
for the type 1 VWD class, the unclassified rate is 0.0476 (Table 4.5), while for the healthy class 
is 0.225 (Table 4.7). These results have an important meaning; if a subject is VWD type 1 
affected, the classifier assign the VWD type 1 class with a high confidence, while if a subject 
is healthy, the classifier shows a relative high uncertainty to assign the healthy class.   
This reflects the difficulties related to the type 1 VWD recognition from the healthy subjects.   
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4.4 VWD type 1 data analysis for classification 
When a subject is classify as affected by type 1 VWD, the second step aims at the classification 
depending on the presence of a VWF gene mutation or not. 
At this scope, a SVM classifier is trained using a training dataset composed by 41 subjects; 30 
are the subjects with VWF gene mutations comprising missense and nonsense mutation and 11 
are the subjects without mutations.     
The most informative indexes are the amount of VWF released and the clearance obtained from 
the PK model, the ratio between the VWF:Ag and VWF:CB measures at the basal state and the 
measure of platelet VWF. The platelet VWF measurement is introduced to take into account 
the VWF synthesis independently of other factors that instead affect the plasma VWF levels 
(Casonato et al, 2016). Since the VWF synthesis mechanism is consider equally in bone narrow 
and in subendothelium, low platelet VWF levels is associated to problems related to its 
synthesis, which can be difficultly detected measuring only the VWF released during the 
DDAVP test.  
 
 
In Figure 4.7a, the platelet VWF level and the amount of VWF released are reported for each 
subject, while in Figure 4.7b the platelet VWF level and clearance are reported for each subject.  
Subjects without gene mutation show an average platelet VWF level higher than the subjects 
with gene mutation with some exception for both missense and nonsense mutation subjects. 
Furthermore, the severe type 1 VWD subjects show a platelet VWF value, which is lower than 
the mild type 1 VWD subjects. 
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Figure 4.7 a) Amount of VWF released and platelet VWF for each subjects affected by type 1 VWD. b) Clearance and platelet 
VWF for each subjects affected by type 1 VWD. 
(a) (b) 
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4.5 Mutation-no mutation classification 
The data discussed in the previous paragraph are not directly used are predictors to train the 
SVM classifier, but a PCA is carried out on the amount of VWF released, clearance, ratio and 
platelet data to reduce the dimensionality and avoid noise measurement; the variance captured 
by each PC is reported in Table 4.10. 
 
Table 4.10 Captured percentage variance for each PC for the PCA carry out on the platelet VWF, the amount of VWF released, 
the clearance and the ratio data for the subjects affected by the type 1 VWD.  
PC1 PC2 PC3 
45.38 % 25.77 % 19.07 % 
 
A SVM classifier with radial basis function is trained on the firsts three PC which capture a 
cumulative variance equal to the 90.2 % of the total. The SVM parameters are obtained through 
a leave-one-out cross-validation and are reported in Table 4.11. In Table 4.11 also the number 
of support vector needed for each class are reported. 
 
Table 4.11 Summarized SVM classifier features and performances. 
 
In cross-validation, the misclassification total error rate is 0.0244 (Table 4.11). Looking at each 
class, no subjects with VWF gene mutation are wrongly classified, while a single subject 
without VWF gene mutation is wrongly classified. 
With the same procedure adopted for the classification between healthy and type 1 VWD class, 
to increase the classifier robustness, a threshold probability is applied for each class assignment. 
In Figure 4.8a the misclassification error rate and the unclassified rate in function of the 
probability thresholds values for each class is shown. In Figure 4.8a the independency of the 
thresholds value with respect to the mutation class misclassification error is evident; in fact no 
misclassified subjects are present in cross validation. In Figure 4.8b the unclassified rate is 
reported in function of the probability thresholds values for each class and increases for both 
classes when the threshold value, for each class, increases.  
 
 
 
 
 
 
γ C 𝑺𝑽𝒕𝒐𝒕 𝑺𝑽𝑴𝒖𝒕 𝑺𝑽𝑵𝒐 𝑴𝒖𝒕 𝑬𝑹𝒕𝒐𝒕
𝑪𝑽  𝑬𝑹𝑴𝒖𝒕
𝑪𝑽  𝑬𝑹𝑵𝒐 𝑴𝒖𝒕
𝑪𝑽  
0.3548 7.08 15 10 5 0.0244  0  0.091  
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(a) 
Figure 4.8 a) Representation of the total error rate of the SVM classifier depending 
on the threshold probability value for each class assignment (mutation or no 
mutation). b) Unclassified rate representation depending on the threshold 
probability value for each class assignment. 
(b) 
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Table 4.12 Misclassification rate for the no mutation class depending on threshold probability values comprises between 0.550 
and 0.650. Bold value corresponds to the chosen pair of threshold probability value. 
  Mutation probability threshold 
  0.550 0.570 0.590 0.610 0.630 0.650 
 
No 
mutation 
probability 
threshold 
0.550 0.0909 0.0909 0.1818 0.0909 0.0909 0.1818 
0.570 0.0909 0.0909 0.0909 0.0909 0.0909 0.1818 
0.590 0.0909 0.0909 0.0909 0.0909 0.1818 0.0909 
0.610 0.0909 0.0909 0.0909 0.0909 0.0909 0.0909 
0.630 0.0909 0.0909 0.0909 0.0909 0.0909 0.0909 
0.650 0.0909 0.0909 0.0909 0.0909 0.0909 0.0909 
 
 
Table 4.13 Unclassified rate for the no mutation class depending on threshold probability values comprises between 0.550 and 
0.650. Bold value corresponds to the chosen pair of threshold probability value. 
  Mutation probability threshold 
  0.550 0.570 0.590 0.610 0.630 0.650 
 
No 
mutation 
probability 
threshold 
0.550 0.0909 0.1818 0.0909 0.1818 0.1818 0.0909 
0.570 0.0909 0.1818 0.1818 0.1818 0.1818 0.0909 
0.590 0.1818 0.1818 0.1818 0.1818 0.0909 0.1818 
0.610 0.0909 0.1818 0.1818 0.1818 0.1818 0.1818 
0.630 0.0909 0.1818 0.1818 0.1818 0.1818 0.1818 
0.650 0.1818 0.1818 0.1818 0.1818 0.0909 0.1818 
 
 
Table 4.14 Unclassified rate for the mutation class depending on threshold probability values comprises between 0.550 and 
0.650. Bold value corresponds to the chosen pair of threshold probability value. 
  Mutation probability threshold 
  0.550 0.570 0.590 0.610 0.630 0.650 
 
No 
mutation 
probability 
threshold 
0.550 0 0 0 0 0 0 
0.570 0 0.0333 0 0 0 0.0333 
0.590 0 0 0.0333 0 0 0.0333 
0.610 0 0.0333 0.0333 0 0.0333 0.0333 
0.630 0.0333 0.0667 0.0333 0.0667 0.0333 0.0333 
0.650 0.0333 0.0333 0.0667 0.0333 0 0.0667 
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Table 4.15 Total unclassified rate depending on threshold probability values comprises between 0.550 and 0.650. Bold value 
corresponds to the chosen pair of threshold probability value. 
  Mutation probability threshold 
  0.550 0.570 0.590 0.610 0.630 0.650 
 
No 
mutation 
probability 
threshold 
0.550 0.0244 0.0488 0.0244 0.0488 0.0488 0.0244 
0.570 0.0244 0.0732 0.0488 0.0488 0.0488 0.0488 
0.590 0.0488 0.0488 0.0732 0.0488 0.0244 0.0732 
0.610 0.0244 0.0732 0.0732 0.0488 0.0732 0.0732 
0.630 0.0488 0.0976 0.0732 0.0976 0.0732 0.0732 
0.650 0.0732 0.0732 0.0976 0.0732 0.0244 0.0976 
 
 
In Table 4.15 the total unclassified rate, which comprise both classes for the threshold values 
between 0.550 and 0.650, is reported. The misclassification error rate in this range is constant 
at the values of 0.0244, meaning that a single subject is wrongly classified. With a threshold 
probability of 0.550 for the mutation category and 0.630 for the no mutation category, the total 
unclassified rate is 0.0488, which means that two subjects are not assigned to a class. Looking 
at the single class unclassified rate (Table 4.13 and Table 4.14 ), only a subject without VWF 
gene mutation and one with VWF gene mutation are not assigned to the belonging class. The 
misclassification rate is zero for the mutation class and is 0.09 for the no mutation class (Table 
4.12). Subject 27 is the one wrongly classified. It shows a high platelet VWF value but levels 
of amount of VWF released and clearance more similar to the missense and nonsense VWF 
gene mutation subjects. The unclassified subject for the mutation class is subject 42, which 
carry a missense mutation and shows a higher platelet VWF than the other missense subjects. 
The unclassified subject without gene mutation is the number 44, which has a platelet VWF 
level at the boundary between the two categories. 
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Conclusions 
Von Willebrand disease diagnosis is a complex task requiring many clinical test to obtain a 
diagnosis.  Because of the many VWD variants and the high heterogeneity observed within the 
same variant the DNA sequencing is often needed to confirm the diagnosis. Type 1 VWD is the 
most common VWD type, covering about the 65% of the total cases and its behaviour is very 
similar to subjects belonging to healthy O blood type. 
A pharmacokinetic model, which was developed to describe the release, proteolysis and the 
clearance of VWF multimers following the injection of DDAVP, has been used to characterized 
the behaviours of subjects affected by type 1 VWD. A clinical dataset if 51 subjects was used 
for the model identification. 
The pharmacokinetic model well represents the general behaviour of the analysed subjects with 
respect the other VWD types. The pharmacokinetic model well characterizes the intra type 1 
variants, showing a clear distinction between the subjects with severe and mild type 1 VWD. A 
bivariate analysis carried out on the amount of VWF released and the clearance shows the 
presence of two clusters; one that identify the subjects with VWF gene mutation (namely 
missense and nonsense) and one that identify mainly subjects without VWF gene mutation.  
In order to achieve a good classification among type 1 and healthy subjects, a SVM classifier 
has been trained using the raw VWF:Ag and VWF:CB data. The SVM classifier has been 
validated with a cross-validation method and 80% of the subjects are correctly classified with 
a high confidence. The remaining 20% of the subjects are equally divided in subjects correctly 
classified but with low confidence and subjects wrongly classified. The classifier shows a 
higher uncertainty for the healthy class assignment respect to the type 1 class, suggesting that 
the affected subjects are more easily recognizable.  
Once a subject is classified as affected by type 1 VWD, a new classification task must be 
performed in order to assess the correct type 1 variant. With this aim, a new SVM classifier has 
been trained using some indexes obtained from the pharmacokinetic model, namely the amount 
of VWF released and the clearance, together with the platelet VWF experimental measurements 
and the VWF ratio. In particular, the classifier identifies if a subject carry or not a gene mutation 
linked to the disease. The SVM classifier has been validated through a cross-validation method 
and correctly classifies with high confidence more than 90% of the subjects. Only 2.5% of the 
subjects are wrongly classified, while 7.5% are correctly classified but with low confidence. 
With the aforementioned two-step classification based on the available historical database, it is 
possible to build an algorithm that is suitable to assist expert clinical practitioners in the 
classification of a new subject.    
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To improve the proposed algorithm a new classification step should be included to distinguish 
between subjects with nonsense mutation and missense mutation, but taking into account other 
variables since from DDAVP data and PK indexes this does not appear to be possible. 
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